Condition:   Prostate Cancer
Intervention:   Other: 11C Acetate Imaging
Sponsors:   Massachusetts General Hospital;   Massachusetts General Hospital
Recruiting - verified May 2012

Condition:   Multiple Myeloma
Interventions:   Drug: Placebo;   Drug: Dexamethasone;   Drug: Bortezomib;   Biological: Tabalumab
Sponsors:   Eli Lilly and Company;   Eli Lilly and Company
Not yet recruiting - verified May 2012

Condition:   Breast Cancer
Intervention:  
Sponsors:   Genentech;   Genentech;   23andMe, Inc.
Recruiting - verified May 2012

Condition:   Advanced HER2-positive Breast Cancer
Interventions:   Drug: LJM716;   Drug: Trastuzumab
Sponsors:   Novartis;   Novartis Pharmaceuticals
Not yet recruiting - verified May 2012

Conditions:   HER2 + Breast Cancer;   HER2 + Gastric Cancer;   Squamous Cell Carcinoma of Head and Neck
Intervention:   Drug: LJM716
Sponsors:   Novartis;   Novartis Pharmaceuticals
Not yet recruiting - verified May 2012

Condition:   Neoplasms, Hematologic
Interventions:   Drug: 200 mg LY2784544;   Drug: 400 mg LY2784544;   Drug: 600 mg LY2784544
Sponsors:   Eli Lilly and Company;   Eli Lilly and Company
Not yet recruiting - verified May 2012

Conditions:   Lung Cancer;   Solid Tumor (Not Breast or Prostate Cancers)
Intervention:   Drug: Cabozantinib
Sponsors:   Massachusetts General Hospital;   Massachusetts General Hospital
Not yet recruiting - verified May 2012

Condition:   Colonic Neoplasms
Intervention:   Behavioral: Behavioral Intervention
Sponsors:   Massachusetts General Hospital;   Massachusetts General Hospital;   National Cancer Institute (NCI)
Not yet recruiting - verified April 2012

Condition:   Neuroblastoma
Interventions:   Biological: ch14.18 -NCI;   Biological: ch14.18-UTC;   Biological: Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF);   Biological: Aldesleukin (IL-2);   Drug: Isotretinoin
Sponsors:   United Therapeutics;   United Therapeutics
Not yet recruiting - verified May 2012

Condition:   Pancreatic Cancer
Interventions:   Drug: FOLFIRINOX;   Drug: Capecitabine;   Radiation: Proton Radiation;   Procedure: Surgery
Sponsors:   Massachusetts General Hospital;   Massachusetts General Hospital;   National Cancer Institute (NCI)
Not yet recruiting - verified May 2012

Condition:   Squamous Cell Carcinoma of the Oropharynx
Intervention:   Radiation: Stereotactic Body Radiotherapy
Sponsors:   Dana-Farber Cancer Institute;   Dana-Farber Cancer Institute
Recruiting - verified April 2012

Condition:   Neuroblastoma
Intervention:  
Sponsors:   New Approaches to Neuroblastoma Therapy Consortium;   New Approaches to Neuroblastoma Therapy Consortium
Recruiting - verified April 2012

Condition:   Multiple Myeloma
Intervention:   Drug: Cabozantinib
Sponsors:   Massachusetts General Hospital;   Massachusetts General Hospital
Not yet recruiting - verified April 2012

Condition:   Ewing's Sarcoma
Intervention:   Drug: Olaparib
Sponsors:   Massachusetts General Hospital;   Massachusetts General Hospital
Not yet recruiting - verified April 2012

Conditions:   Dose Escalation;   Safety;   Preliminary Efficacy;   Advanced Solid Tumors;   Metastatic Breast Cancer;   Advanced Pancreatic Adenocarcinoma;   Metastatic Colorectal Cancer;   Recurrent Glioblastoma Multiforme
Intervention:   Drug: LDE225 and BKM120
Sponsors:   Novartis;   Novartis Pharmaceuticals
Not yet recruiting - verified May 2012

Conditions:   Carcinoid Tumor of the Small Bowel;   Neuroendocrine Tumour
Interventions:   Drug: Octreotide;   Drug: Octreotide;   Drug: 177Lu-DOTA0-Tyr3-Octreotate
Sponsors:   Advanced Accelerator Applications;   Advanced Accelerator Applications;   Pierrel Research Europe GmbH
Not yet recruiting - verified April 2012

Condition:   Breast Cancer
Interventions:   Drug: tivantinib;   Genetic: fluorescence in situ hybridization;   Genetic: gene expression analysis;   Genetic: mutation analysis;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis
Sponsors:   National Cancer Institute (NCI);   Dana-Farber Cancer Institute;   National Cancer Institute (NCI)
Recruiting - verified April 2012

Condition:   Prostate Cancer
Interventions:   Drug: Cabozantinib;   Drug: Abiraterone
Sponsors:   Dana-Farber Cancer Institute;   Dana-Farber Cancer Institute
Recruiting - verified April 2012

Condition:   Breast Cancer
Intervention:   Other: MRI
Sponsors:   Dana-Farber Cancer Institute;   Dana-Farber Cancer Institute
Recruiting - verified March 2012

Conditions:   Non-small Cell Lung Cancer Metastatic;   Small Cell Lung Carcinoma
Intervention:   Other: therapeutic interventions
Sponsors:   Vanderbilt-Ingram Cancer Center;   David P. Carbone, M.D. PhD;   Addario Lung Cancer Institute (ALCMI)
Recruiting - verified April 2012

Conditions:   Acute Lymphoblastic Leukemia;   Lymphoblastic Lymphoma
Interventions:   Drug: SC-PEG;   Drug: Oncaspar
Sponsors:   Dana-Farber Cancer Institute;   Dana-Farber Cancer Institute;   Sigma Tau;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Non-Small Cell Lung Cancer
Interventions:   Radiation: Proton Beam Radiation;   Drug: Cisplatin;   Drug: Etoposide
Sponsors:   Massachusetts General Hospital;   Massachusetts General Hospital
Recruiting - verified March 2012

Condition:   Carcinoma, Midline
Intervention:   Drug: GSK525762
Sponsors:   GlaxoSmithKline;   GlaxoSmithKline
Recruiting - verified May 2012

Conditions:   KRAS Mutated Colorectal Adenocarcinoma.;   Metastatic Pancreatic Adenocarcinoma;   BRAF Mutated Melanoma
Intervention:   Drug: MEK162 + AMG 479
Sponsors:   Novartis;   Novartis Pharmaceuticals
Not yet recruiting - verified April 2012

Condition:   Breast Cancer
Intervention:   Drug: Ruxolitinib
Sponsors:   Dana-Farber Cancer Institute;   Dana-Farber Cancer Institute
Not yet recruiting - verified March 2012

Condition:   Neoplasms
Interventions:   Drug: GDC-0973;   Drug: GDC-0068
Sponsors:   Genentech;   Genentech
Not yet recruiting - verified March 2012

Condition:   Breast Neoplasms
Interventions:   Drug: lapatinib ditosylate;   Biological: trastuzumab
Sponsors:   Washington University School of Medicine;   Washington University School of Medicine
Not yet recruiting - verified March 2012

Condition:   Breast Cancer
Interventions:   Drug: AC regimen;   Drug: TAC regimen;   Drug: cyclophosphamide;   Drug: docetaxel;   Drug: doxorubicin hydrochloride;   Drug: paclitaxel
Sponsors:   National Cancer Institute (NCI);   National Surgical Adjuvant Breast and Bowel Project (NSABP);   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Lung Cancer
Interventions:   Drug: Afatinib;   Radiation: Radiation;   Drug: Cisplatin;   Drug: Pemetrexed;   Procedure: Surgery
Sponsors:   Massachusetts General Hospital;   Massachusetts General Hospital
Not yet recruiting - verified March 2012

Condition:   Breast Cancer
Intervention:   Drug: ARQ 197
Sponsors:   Dana-Farber Cancer Institute;   Dana-Farber Cancer Institute
Not yet recruiting - verified March 2012

Condition:   Glioblastoma, Glioma
Intervention:   Drug: GDC-0084
Sponsors:   Genentech;   Genentech
Recruiting - verified May 2012

Condition:   Non-Hodgkin's Lymphoma
Interventions:   Drug: Rituximab;   Drug: MGD
Sponsors:   Spectrum Pharmaceuticals, Inc;   Spectrum Pharmaceuticals, Inc
Recruiting - verified April 2012

Condition:   Breast Cancer
Interventions:   Drug: Fulvestrant;   Drug: Ganetespib
Sponsors:   Dana-Farber Cancer Institute;   Dana-Farber Cancer Institute
Not yet recruiting - verified March 2012

Condition:   Brain Tumors
Intervention:  
Sponsors:   Beth Israel Deaconess Medical Center;   Beth Israel Deaconess Medical Center;   National Cancer Institute (NCI)
Recruiting - verified February 2012

Conditions:   Obstruction of Biliary Tree;   Biliary Tract Cancer;   Biliary Tract Neoplasms
Intervention:   Device: Radiofrequency ablation catheter (Habib EndoHBP)
Sponsors:   Massachusetts General Hospital;   Massachusetts General Hospital
Recruiting - verified February 2012

Condition:   Breast Cancer
Intervention:   Other: Bioimpedance Spectroscopy
Sponsors:   Massachusetts General Hospital;   Massachusetts General Hospital
Recruiting - verified February 2012

Condition:   Papillary Thyroid Carcinoma
Intervention:   Drug: GSK2118436
Sponsors:   Massachusetts General Hospital;   Massachusetts General Hospital;   GlaxoSmithKline
Not yet recruiting - verified April 2012

Condition:   Solid Tumors Harboring a BRAF V600 Mutation
Interventions:   Drug: LGX818;   Drug: MEK162
Sponsors:   Novartis;   Novartis Pharmaceuticals
Not yet recruiting - verified April 2012

Condition:   Hodgkin Lymphoma
Interventions:   Drug: Brentuximab Vedotin;   Drug: Adriamycin, vinblastine, and dacarbazine
Sponsors:   Massachusetts General Hospital;   Massachusetts General Hospital;   Dana-Farber Cancer Institute;   Beth Israel Deaconess Medical Center;   Seattle Genetics, Inc.
Recruiting - verified April 2012

Condition:   Breast Cancer
Intervention:   Drug: PM01183
Sponsors:   PharmaMar;   PharmaMar
Not yet recruiting - verified January 2012

Conditions:   Non-Hodgkin's Lymphoma (NHL);   Hodgkin's Disease;   Chronic Lymphocytic Leukemia (CLL);   Acute Myelogenous Leukemia (AML);   Acute Lymphoblastic Leukemia (ALL);   MDS
Intervention:   Biological: Single FT1050 treated UCB unit
Sponsors:   Fate Therapeutics;   Fate Therapeutics
Recruiting - verified February 2012

Condition:   Carcinoma, Non-Small-Cell Lung
Interventions:   Drug: erlotinib;   Drug: afatinib
Sponsors:   Boehringer Ingelheim Pharmaceuticals;   Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012

Condition:   Advanced Cancer
Intervention:   Behavioral: video decision aid
Sponsors:   Massachusetts General Hospital;   Massachusetts General Hospital;   Stanford University
Recruiting - verified April 2012

Condition:   Prostatic Neoplasms
Intervention:   Drug: Radium-223 chloride (BAY88-8223)
Sponsors:   Bayer;   Bayer
Available - verified April 2012

Condition:   Acute Lymphoblastic Leukemia
Interventions:   Drug: Everolimus;   Drug: Prednisone;   Drug: Vincristine;   Drug: PEG-Asparaginase;   Drug: Doxorubicin;   Drug: Dexrazoxane
Sponsors:   Dana-Farber Cancer Institute;   Dana-Farber Cancer Institute;   Novartis
Recruiting - verified January 2012

Condition:   Breast Cancer
Interventions:   Behavioral: Exercise;   Behavioral: Surgical preparation program
Sponsors:   Dana-Farber Cancer Institute;   Dana-Farber Cancer Institute;   Yale University;   Susan G. Komen Breast Cancer Foundation
Recruiting - verified January 2012

Condition:   Metastatic Colorectal Cancer
Interventions:   Drug: FOLFOX + bevacizumab;   Dietary Supplement: Vitamin D;   Dietary Supplement: Vitamin D
Sponsors:   Dana-Farber Cancer Institute;   Dana-Farber Cancer Institute
Recruiting - verified April 2012

Condition:   Non-small-cell Lung Cancer
Interventions:   Radiation: SBRT (stereotactic body radiotherapy);   Radiation: SBPT (stereotactic body proton therapy)
Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center;   National Institutes of Health (NIH)
Not yet recruiting - verified January 2012

Condition:   Breast Cancer
Intervention:   Radiation: External Beam Partial-Breast Irradiation
Sponsors:   Massachusetts General Hospital;   Massachusetts General Hospital;   Beth Israel Deaconess Medical Center;   Brigham and Women's Hospital
Recruiting - verified May 2012

Condition:   Melanoma
Interventions:   Biological: Ipilimumab;   Biological: Ipilimumab
Sponsors:   Bristol-Myers Squibb;   Bristol-Myers Squibb
Recruiting - verified March 2012

Condition:   Malignant Melanoma
Intervention:   Drug: vemurafenib
Sponsors:   Hoffmann-La Roche;   Hoffmann-La Roche
Not yet recruiting - verified May 2012

Conditions:   Colon Cancer;   Rectal Cancer
Intervention:  
Sponsors:   University of Michigan;   University of Michigan;   Early Detection Research Network
Recruiting - verified January 2012

Conditions:   Rhabdomyosarcoma and Other Soft Tissue Sarcomas;   Ewing's Sarcoma Family of Tumors;   Osteosarcoma;   Neuroblastoma;   Brain Tumors
Interventions:   Drug: sorafenib;   Drug: irinotecan
Sponsors:   Children's Research Institute;   Children's Research Institute
Recruiting - verified January 2012

Condition:   Multiple Myeloma
Interventions:   Drug: ACE-011;   Drug: Lenalidomide;   Drug: Dexamethasone
Sponsors:   Massachusetts General Hospital;   Massachusetts General Hospital
Recruiting - verified May 2012

Condition:   Multiple Myeloma
Interventions:   Drug: TH-302;   Drug: TH-302;   Drug: TH-302 and bortezomib
Sponsors:   Threshold Pharmaceuticals;   Threshold Pharmaceuticals
Recruiting - verified April 2012

Conditions:   Head and Neck Cancer;   Kidney Cancer;   Liver Cancer;   Sarcoma
Interventions:   Drug: sorafenib tosylate;   Genetic: gene expression analysis;   Genetic: mutation analysis;   Genetic: polymerase chain reaction;   Other: enzyme-linked immunosorbent assay;   Other: laboratory biomarker analysis;   Other: pharmacological study
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Conditions:   Lung Cancer;   Breast Cancer;   Colorectal Cancer;   Cholangiocarcinoma;   Solid Tumors
Intervention:   Drug: BKM120
Sponsors:   Massachusetts General Hospital;   Massachusetts General Hospital;   Novartis Pharmaceuticals
Recruiting - verified April 2012

Conditions:   Advanced NET of GI Origin;   Advanced NET of Lung Origin;   Neuroendocrine Tumors
Interventions:   Drug: Everolimus;   Drug: Everolimus Placebo
Sponsors:   Novartis;   Novartis Pharmaceuticals
Recruiting - verified April 2012

Condition:   Prostate Cancer
Intervention:   Drug: PLX3397
Sponsors:   Plexxikon;   Plexxikon
Recruiting - verified May 2012

Condition:   Non-small Cell Lung Cancer (NSCLC) With Brain Metastases
Intervention:   Drug: GRN1005
Sponsors:   Geron Corporation;   Geron Corporation
Recruiting - verified April 2012

Condition:   Non-Small Cell Lung Cancer
Interventions:   Drug: onartuzumab;   Drug: Placebo;   Drug: paclitaxel;   Drug: cisplatin/carboplatin
Sponsors:   Genentech;   Genentech
Not yet recruiting - verified January 2012

Condition:   Non-Small Cell Lung Cancer
Interventions:   Drug: RO5490258;   Drug: bevacizumab [Avastin];   Drug: pemetrexed;   Drug: Placebo;   Drug: cisplatin/carboplatin;   Drug: paclitaxel
Sponsors:   Genentech;   Genentech
Not yet recruiting - verified January 2012

Conditions:   Glioblastoma;   Small Cell Glioblastoma;   Giant Cell Glioblastoma;   Gliosarcoma;   Glioblastoma With Oligodendroglial Component;   Recurrent Glioblastoma;   Relapsed Glioblastoma
Interventions:   Drug: Bevacizumab;   Drug: Rindopepimut (CDX-110) with GM-CSF;   Drug: KLH
Sponsors:   Celldex Therapeutics;   Celldex Therapeutics
Recruiting - verified May 2012

Condition:   Multiple Myeloma
Interventions:   Drug: Pomalidomide;   Drug: Bortezomib;   Drug: Dexamethasone
Sponsors:   Celgene Corporation;   Celgene Corporation;   Multiple Myeloma Research Consortium
Recruiting - verified April 2012

Condition:   Breast Cancer
Interventions:   Drug: HKI-272;   Drug: HKI-272;   Procedure: Surgical Resection
Sponsors:   Dana-Farber Cancer Institute;   Dana-Farber Cancer Institute;   Translational Breast Cancer Research Consortium
Recruiting - verified February 2012

Condition:   Cancer
Intervention:  
Sponsors:   Caris Science, Inc.;   Caris Science, Inc.
Recruiting - verified February 2012

Conditions:   Primary Tumor;   Metastatic Cancer
Interventions:   Radiation: Radiosurgery/SBRT;   Radiation: External Beam Radiation Therapy
Sponsors:   Dana-Farber Cancer Institute;   Beth Israel Deaconess Medical Center
Recruiting - verified February 2012

Condition:   Prostate Cancer
Intervention:   Radiation: CyberKnife Boost
Sponsors:   Boston Medical Center;   Boston Medical Center
Recruiting - verified December 2011

Conditions:   Metastatic Colorectal Cancer;   Colorectal Cancer
Interventions:   Drug: MORAb-004;   Drug: Placebo
Sponsors:   Morphotek;   Morphotek
Recruiting - verified May 2012

Condition:   Pancreatic Cancer
Intervention:   Drug: LDE225+gemcitabine
Sponsors:   Novartis;   Novartis Pharmaceuticals
Recruiting - verified April 2012

Condition:   Pancreatic Cancer
Intervention:   Drug: LDE225; Fluorouracil; Leucovorin; Oxaliplatin; Irinotecan
Sponsors:   Massachusetts General Hospital;   Massachusetts General Hospital;   Dana-Farber Cancer Institute
Recruiting - verified December 2011

Conditions:   Melanoma;   Metastatic Melanoma
Interventions:   Drug: Vemurafenib;   Drug: Bevacizumab
Sponsors:   Melanoma Research Foundation Breakthrough Consortium;   Melanoma Research Foundation Breakthrough Consortium;   Genentech
Not yet recruiting - verified April 2012

Condition:   Multiple Myeloma
Interventions:   Drug: Ganetespib Dexamethasone;   Drug: Bortezomib;   Drug: Dexamethasone
Sponsors:   Emory University;   Emory University;   Multiple Myeloma Research Consortium
Recruiting - verified March 2012

Conditions:   Thrombocytopenia;   Multiple Myeloma
Intervention:   Drug: Eltrombopag
Sponsors:   Dana-Farber Cancer Institute;   Dana-Farber Cancer Institute
Recruiting - verified April 2012

Conditions:   Metastatic Solid Tumor;   Breast Cancer;   Ovarian Cancer
Intervention:   Drug: Rucaparib
Sponsors:   Clovis Oncology, Inc.;   Clovis Oncology, Inc.
Recruiting - verified May 2012

Condition:   HER2 Negative Breast Cancer
Interventions:   Biological: NeuVax vaccine;   Biological: Leukine (sargramostim, GM-CSF) and water for injection
Sponsors:   Galena Biopharma, Inc.;   Galena Biopharma, Inc.
Recruiting - verified May 2012

Conditions:   Acute Lymphoblastic Leukemia;   Precursor B-Cell Lymphoblastic Leukemia;   Precursor T-Cell Lymphoblastic Leukemia
Interventions:   Drug: Decitabine;   Drug: Vorinostat;   Drug: Vincristine;   Drug: Dexamethasone;   Drug: Mitoxantrone;   Drug: Pegaspargase;   Drug: Methotrexate
Sponsors:   Therapeutic Advances in Childhood Leukemia Consortium;   Therapeutic Advances in Childhood Leukemia Consortium
Recruiting - verified March 2012

Conditions:   Relapsed Peripheral T-Cell Lymphoma;   Refractory Peripheral T-Cell Lymphoma
Interventions:   Drug: Alisertib;   Drug: Pralatrexate;   Drug: Romidepsin;   Drug: Gemcitabine
Sponsors:   Millennium Pharmaceuticals, Inc.;   Millennium Pharmaceuticals, Inc.
Recruiting - verified May 2012

Conditions:   Breast Cancer;   Brain Metastases
Interventions:   Drug: GRN1005;   Drug: Trastuzumab
Sponsors:   Geron Corporation;   Geron Corporation
Recruiting - verified May 2012

Conditions:   Glioblastoma;   Small Cell Glioblastoma;   Giant Cell Glioblastoma;   Gliosarcoma;   Glioblastoma With Oligodendroglial Component
Interventions:   Drug: Rindopepimut (CDX-110) with GM-CSF;   Drug: Temozolomide;   Drug: KLH
Sponsors:   Celldex Therapeutics;   Celldex Therapeutics
Recruiting - verified May 2012

Condition:   Multiple Myeloma
Intervention:   Drug: PCI-32765
Sponsors:   Pharmacyclics;   Pharmacyclics
Recruiting - verified May 2012

Condition:   Acute Myeloid Leukemia
Intervention:   Drug: AZD1208
Sponsors:   AstraZeneca;   AstraZeneca
Recruiting - verified May 2012

Condition:   Cancer - Solid Tumors
Interventions:   Drug: BMS-663513 (Anti-CD137);   Drug: BMS-663513 (Anti-CD137);   Drug: BMS-663513 (Anti-CD137)
Sponsors:   Bristol-Myers Squibb;   Bristol-Myers Squibb
Recruiting - verified November 2011

Condition:   Colorectal Cancer
Interventions:   Drug: GS-6624;   Drug: FOLFIRI;   Drug: GS-6624;   Drug: FOLFIRI;   Drug: GS-6624;   Drug: FOLFIRI;   Drug: Placebo;   Drug: FOLFIRI
Sponsors:   Gilead Sciences;   Gilead Sciences
Recruiting - verified March 2012

Condition:   Follicular Lymphoma
Interventions:   Drug: Rituximab;   Drug: Lenalidomide;   Drug: Rituximab-CHOP;   Drug: Rituximab-CVP;   Drug: Rituximab-Bendamustine
Sponsors:   Celgene Corporation;   Celgene Corporation;   Groupe d'Etude des Lymphomes de l'Adulte - Recherche Clinique
Recruiting - verified April 2012

Condition:   Breast Cancer
Intervention:  
Sponsors:   Dana-Farber Cancer Institute;   Dana-Farber Cancer Institute
Recruiting - verified November 2011

Condition:   Prostate Cancer
Interventions:   Drug: Radiation;   Drug: Androgen Deprivation Therapy (ADT);   Other: Standard of care;   Drug: L-BLP25
Sponsors:   EMD Serono;   EMD Serono
Recruiting - verified December 2011

Condition:   3rd Line GIST
Intervention:   Drug: STI571 + BKM120
Sponsors:   Novartis;   Novartis Pharmaceuticals
Not yet recruiting - verified April 2012

Condition:   Multiple Myeloma
Interventions:   Biological: Elotuzumab;   Drug: Bortezomib;   Drug: Dexamethasone;   Drug: Dexamethasone;   Drug: Dexamethasone;   Drug: Dexamethasone
Sponsors:   Bristol-Myers Squibb;   Bristol-Myers Squibb;   Abbott Biotherapeutics Corp.
Recruiting - verified February 2012

Conditions:   Carcinoid Tumor;   Pancreatic Neuroendocrine Tumor
Intervention:   Drug: Cabozantinib
Sponsors:   Massachusetts General Hospital;   Massachusetts General Hospital
Not yet recruiting - verified November 2011

Conditions:   Acute Lymphoid Leukemia;   Acute Myeloid Leukemia;   Chronic Lymphocytic Leukemia;   Multiple Myeloma;   Solid Tumors
Intervention:   Drug: brentuximab vedotin
Sponsors:   Seattle Genetics, Inc.;   Seattle Genetics, Inc.
Recruiting - verified April 2012

Conditions:   Adenoid Cystic Carcinoma;   Squamous Cell Carcinoma;   Sinonasal Carcinoma;   Sinonasal Undifferentiated Carcinoma
Interventions:   Radiation: Proton radiation therapy;   Radiation: Intensity-modulated radiotherapy
Sponsors:   Massachusetts General Hospital;   Massachusetts General Hospital;   National Institutes of Health (NIH);   National Cancer Institute (NCI)
Recruiting - verified April 2012

Condition:   Non-Small Cell Lung Cancer
Interventions:   Drug: onartuzumab [MetMAb];   Drug: erlotinib [Tarceva];   Drug: Placebo
Sponsors:   Genentech;   Genentech;   Hoffmann-La Roche
Recruiting - verified January 2012

Condition:   Acute Lymphoblastic Leukemia
Intervention:   Drug: Blinatumomab
Sponsors:   Micromet GmbH;   Micromet GmbH
Recruiting - verified February 2012

Conditions:   Renal Cell Carcinoma;   Clear-cell Metastatic Renal Cell Carcinoma
Interventions:   Biological: BMS-936558;   Drug: Sunitinib;   Drug: Pazopanib
Sponsors:   Bristol-Myers Squibb;   Bristol-Myers Squibb;   Ono Pharmaceutical Company, Ltd.
Recruiting - verified March 2012

Condition:   Leukemia, Pediatric
Intervention:   Drug: Dasatinib
Sponsors:   Bristol-Myers Squibb;   Bristol-Myers Squibb;   Children's Oncology Group;   EsPhALL - European Intergroup Study on Post Induction Treatment of Philadelphia Positive Acute Lymphoblastic Leukaemia with Imatinib
Recruiting - verified April 2012

Condition:   Endometrial Carcinoma
Intervention:   Drug: GDC-0980
Sponsors:   Genentech;   Genentech
Recruiting - verified October 2011

Condition:   HIV Infections
Interventions:   Biological: Quadrivalent HPV Vaccine;   Biological: Placebo Vaccine
Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2012

Condition:   Myelodysplastic Syndrome
Interventions:   Drug: Siltuximab + BSC;   Drug: Placebo + BSC
Sponsors:   Janssen Research & Development, LLC;   Janssen Research & Development, LLC
Recruiting - verified April 2012

Conditions:   Colorectal Cancer;   Squamous Cell Head and Neck Cancer;   Non-small Cell Lung Cancer;   Triple Negative Breast Cancer;   Other Tumors With EGFR Dependence
Interventions:   Drug: MM-121 (SAR256212);   Drug: Irinotecan;   Drug: Cetuximab
Sponsors:   Merrimack Pharmaceuticals;   Merrimack Pharmaceuticals;   Sanofi-Aventis
Recruiting - verified January 2012

Condition:   Non-Small Cell Lung Cancer
Intervention:  
Sponsors:   Precision Therapeutics;   Precision Therapeutics
Recruiting - verified January 2012

Condition:   HIV Infection
Intervention:  
Sponsors:   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);   National Institute on Drug Abuse (NIDA);   National Institute of Mental Health (NIMH)
Recruiting - verified November 2011

Condition:   Squamous Cell Lung Cancer
Intervention:   Drug: Dasatinib
Sponsors:   Dana-Farber Cancer Institute;   Dana-Farber Cancer Institute
Recruiting - verified December 2011

Condition:   Advanced and Selected Solid Tumors
Intervention:   Drug: BYL719 plus MEK162
Sponsors:   Novartis;   Novartis Pharmaceuticals
Recruiting - verified May 2012

Conditions:   Esophageal Cancer;   Precancerous Condition
Interventions:   Drug: metformin hydrochloride;   Other: placebo
Sponsors:   National Cancer Institute (NCI);   Mayo Clinic;   National Cancer Institute (NCI)
Recruiting - verified January 2012

Conditions:   Advanced Malignancies;   Carcinoma, Non-Small-Cell Lung;   Anaplastic Large Cell Lymphoma;   Diffuse Large Cell Lymphoma;   Inflammatory Myofibroblastic Tumors
Intervention:   Drug: AP26113
Sponsors:   Ariad Pharmaceuticals;   Ariad Pharmaceuticals
Recruiting - verified April 2012

Conditions:   Sarcoma;   Wilm's Tumor;   Lymphoma;   Neuroblastoma
Intervention:   Drug: Ipilimumab(anti-CTLA-4 antibody)
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified March 2012

Condition:   Breast Cancer
Intervention:   Drug: Cabozantinib
Sponsors:   Massachusetts General Hospital;   Massachusetts General Hospital;   Exelixis
Recruiting - verified January 2012

Condition:   Smoldering Multiple Myeloma
Intervention:   Biological: Elotuzumab (BMS-901608; HuLuc63)
Sponsors:   Bristol-Myers Squibb;   Bristol-Myers Squibb;   Abbott Biotherapeutics Corp.
Recruiting - verified February 2012

Condition:   Colon Cancer
Intervention:   Drug: Metformin
Sponsors:   Tufts Medical Center;   Tufts Medical Center
Recruiting - verified May 2012

Condition:   Prostate Cancer
Interventions:   Biological: AdV-tk + valacyclovir;   Biological: Placebo + valacyclovir
Sponsors:   Advantagene, Inc.;   Advantagene, Inc.
Recruiting - verified May 2012

Condition:   Cancer
Intervention:   Drug: Metformin
Sponsors:   Tufts Medical Center;   Tufts Medical Center
Recruiting - verified November 2011

Condition:   Renal Cell Carcinoma
Interventions:   Drug: CT-011;   Biological: DC/RCC fusion vaccine
Sponsors:   Dana-Farber Cancer Institute;   Beth Israel Deaconess Medical Center;   National Institutes of Health (NIH);   National Cancer Institute (NCI)
Recruiting - verified February 2012

Condition:   Waldenstrom's Macroglobulinemia
Interventions:   Drug: Dexamethasone;   Drug: Carfilzomib;   Drug: Rituximab
Sponsors:   Dana-Farber Cancer Institute;   Dana-Farber Cancer Institute;   Onyx Pharmaceuticals
Recruiting - verified November 2011

Conditions:   brca1 Mutation Carrier;   brca2 Mutation Carrier;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions:   Drug: carboplatin;   Drug: dinaciclib;   Drug: veliparib;   Other: circulating tumor cell analysis;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis;   Other: pharmacological study
Sponsors:   National Cancer Institute (NCI);   Dana-Farber Cancer Institute;   National Cancer Institute (NCI)
Recruiting - verified January 2012

Condition:   Advanced Solid Tumor
Interventions:   Drug: MSC2015103B;   Drug: MSC2015103B
Sponsors:   EMD Serono;   EMD Serono
Recruiting - verified March 2012

Condition:   Breast Cancer
Interventions:   Drug: fulvestrant;   Drug: GDC-0941;   Drug: GDC-0980;   Drug: placebo
Sponsors:   Genentech;   Genentech
Recruiting - verified April 2012

Condition:   Advanced Solid Tumors
Interventions:   Drug: E7050 plus E7080;   Drug: E7080 plus E7050;   Drug: E7050 plus E7080 or E7080 alone plus E7050 add-on therapy;   Drug: E7050 plus E7080;   Drug: E7050
Sponsors:   Eisai Inc.;   Eisai Inc.
Recruiting - verified March 2012

Conditions:   Pathology of Posterior Fossa;   Lung Cancer;   Flank Pain;   Urolithiasis;   Focal Liver Lesion
Intervention:  
Sponsors:   GE Healthcare;   GE Healthcare;   American College of Radiology - Image Metrix
Recruiting - verified January 2012

Condition:   Lymphedema
Intervention:  
Sponsors:   Massachusetts General Hospital;   Massachusetts General Hospital;   National Cancer Institute (NCI)
Recruiting - verified January 2012

Condition:   Uveal Melanoma
Intervention:   Drug: AEB071
Sponsors:   Novartis;   Novartis Pharmaceuticals
Recruiting - verified March 2012

Conditions:   Melanoma;   Malignant Melanoma
Intervention:   Drug: CT-011
Sponsors:   CureTech Ltd;   CureTech Ltd
Recruiting - verified January 2012

Conditions:   Uterine Fibroids;   Heavy Uterine Bleeding
Interventions:   Drug: placebo;   Drug: elagolix, elagolix sodium;   Drug: Placebo;   Drug: elagolix, elagolix sodium;   Other: Elagolix Dose 1 plus estradiol/norethindrone acetate;   Drug: Placebo Cohort 4;   Drug: Elagolix, elagolix sodium;   Drug: Elagolix, elagolix sodium
Sponsors:   Abbott;   Abbott;   Neurocrine Biosciences
Recruiting - verified April 2012

Condition:   Breast Cancer
Interventions:   Device: AeroForm Patient Controlled Tissue Expander;   Procedure: Implantation of Saline Tissue Expander
Sponsors:   AirXpanders, Inc.;   AirXpanders, Inc.
Recruiting - verified April 2012

Condition:   Breast Cancer
Intervention:   Other: Non invasive venous ultrasound
Sponsors:   Massachusetts General Hospital;   Massachusetts General Hospital;   National Cancer Institute (NCI)
Recruiting - verified April 2012

Condition:   Cachexia
Interventions:   Drug: BYM338 active drug;   Drug: Placebo
Sponsors:   Novartis;   Novartis
Recruiting - verified April 2012

Condition:   Metastatic Pancreatic Adenocarcinoma
Interventions:   Drug: Number 1 - Capecitabine and ruxolitinib;   Drug: Number 2 - Capecitabine and placebo
Sponsors:   Incyte Corporation;   Incyte Corporation
Recruiting - verified May 2012

Condition:   Multiple Myeloma
Intervention:   Procedure: Blood draws
Sponsors:   Dana-Farber Cancer Institute;   Beth Israel Deaconess Medical Center
Recruiting - verified November 2011

Conditions:   ER Positive, Her2 Negative Breast Cancer Patients;   Triple Negative Breast Cancer Patients
Interventions:   Drug: MM-121 (SAR256212) plus paclitaxel;   Drug: Paclitaxel
Sponsors:   Merrimack Pharmaceuticals;   Merrimack Pharmaceuticals;   Sanofi-Aventis
Recruiting - verified April 2012

Condition:   Endometrial Neoplasms
Interventions:   Drug: PF-04691502;   Drug: PF-05212384;   Drug: PF-04691502;   Drug: PF-05212384
Sponsors:   Pfizer;   Pfizer
Recruiting - verified May 2012

Condition:   Breast Cancer
Interventions:   Drug: trastuzumab emtansine;   Drug: anti-cancer therapy
Sponsors:   Genentech;   Genentech
Recruiting - verified March 2012

Condition:   Metastatic Solid Tumors
Intervention:   Drug: INK1117
Sponsors:   Intellikine;   Intellikine
Recruiting - verified February 2012

Condition:   Glioblastoma
Interventions:   Drug: BKM120 + temozolomide;   Drug: BKM120 +temozolomide with/without radiotherapy
Sponsors:   Novartis;   Novartis Pharmaceuticals
Recruiting - verified May 2012

Condition:   Leukemia
Interventions:   Drug: bortezomib;   Drug: decitabine
Sponsors:   National Cancer Institute (NCI);   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Conditions:   Lymphoma, B-Cell;   Lymphoma, Non-Hodgkin;   Lymphoma, T-Cell
Intervention:   Drug: brentuximab vedotin
Sponsors:   Seattle Genetics, Inc.;   Seattle Genetics, Inc.
Recruiting - verified April 2012

Condition:   Pancreatic Cancer, Metastatic
Interventions:   Drug: Gemcitabine, Erlotinib, OSI-906;   Drug: Gemcitabine, Erlotinib
Sponsors:   Dana-Farber Cancer Institute;   Dana-Farber Cancer Institute
Not yet recruiting - verified May 2012

Condition:   Advanced Cancer
Intervention:   Drug: OPB-51602
Sponsors:   Otsuka Pharmaceutical Development & Commercialization, Inc.;   Otsuka Pharmaceutical Development & Commercialization, Inc.
Recruiting - verified November 2011

Condition:   Pancreatic Cancer
Interventions:   Drug: Capecitabine;   Drug: Hydroxychloroquine;   Radiation: Proton Radiation Therapy
Sponsors:   Massachusetts General Hospital;   Massachusetts General Hospital
Recruiting - verified December 2011

Conditions:   Non-Hodgkin's Lymphoma;   Hodgkin's Lymphoma;   Multiple Myeloma;   Chronic Lymphocytic Leukemia;   Acute Myelogenous Leukemia
Interventions:   Drug: Fludarabine;   Drug: Melphalan;   Radiation: Total Body Radiation;   Biological: Cord Blood
Sponsors:   Massachusetts General Hospital;   Massachusetts General Hospital
Recruiting - verified December 2011

Condition:   Advanced Solid Tumors
Intervention:   Drug: ABT-806
Sponsors:   Abbott;   Abbott
Recruiting - verified May 2012

Condition:   Oral Mucositis
Interventions:   Biological: ALD518;   Drug: 0.9% saline
Sponsors:   Alder Biopharmaceuticals, Inc.;   Alder Biopharmaceuticals, Inc.
Recruiting - verified April 2012

Conditions:   Lymphoblastic Leukemia, Acute, Childhood;   Myelogenous Leukemia, Acute, Childhood
Interventions:   Drug: AC220;   Drug: Cytarabine;   Drug: Etoposide;   Drug: Methotrexate
Sponsors:   Therapeutic Advances in Childhood Leukemia Consortium;   Therapeutic Advances in Childhood Leukemia Consortium;   Ambit Biosciences Corporation
Recruiting - verified September 2011

Conditions:   Cancer;   Thyroid
Intervention:  
Sponsors:   Boston Medical Center;   Boston Medical Center;   Fraunhofer USA
Recruiting - verified December 2011

Condition:   Malignancies
Intervention:   Drug: PWT33597 mesylate
Sponsors:   Pathway Therapeutics, Inc.;   Pathway Therapeutics, Inc.
Recruiting - verified October 2011

Conditions:   Non-small Cell Lung Cancer;   Small Cell Lung Cancer;   Mesothelioma;   Esophageal Cancer;   Gastric Cancer;   Liver Cancer;   Biliary Cancer
Intervention:  
Sponsors:   Massachusetts General Hospital;   Massachusetts General Hospital
Recruiting - verified April 2012

Conditions:   Cognitive/Functional Effects;   Leukemia;   Neurotoxicity;   Pain;   Therapy-related Toxicity
Interventions:   Drug: clofarabine;   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: hydrocortisone sodium succinate;   Drug: leucovorin calcium;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: pegaspargase;   Drug: prednisone;   Drug: thioguanine;   Drug: vincristine sulfate;   Radiation: selective external radiation therapy
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Non-small Cell Lung Cancer
Intervention:   Radiation: SBRT with proton beam radiation
Sponsors:   Massachusetts General Hospital;   Massachusetts General Hospital
Recruiting - verified January 2012

Conditions:   Colorectal Neoplasms;   Digestive System Diseases;   Colonic Diseases;   Colorectal Cancer
Intervention:  
Sponsors:   Exact Sciences Corporation;   Exact Sciences Corporation
Recruiting - verified August 2011

Condition:   Chordoma
Interventions:   Drug: Nilotinib;   Radiation: Radiation therapy
Sponsors:   Massachusetts General Hospital;   Massachusetts General Hospital
Recruiting - verified April 2012

Condition:   Lymphoma
Intervention:   Drug: SAR245409
Sponsors:   Sanofi-Aventis;   Sanofi-Aventis
Recruiting - verified May 2012

Conditions:   Squamous Cell Lung Cancer;   Lung Cancer
Intervention:  
Sponsors:   Massachusetts General Hospital;   Massachusetts General Hospital;   National Cancer Institute (NCI);   NinePoint Medical
Recruiting - verified April 2012

Condition:   Melanoma
Interventions:   Drug: Ipilimumab (BMS-734016);   Biological: Vemurafenib
Sponsors:   Bristol-Myers Squibb;   Bristol-Myers Squibb;   Roche-Genentech
Recruiting - verified November 2011

Condition:   Advanced Cancer
Intervention:   Drug: LY2835219
Sponsors:   Eli Lilly and Company;   Eli Lilly and Company
Recruiting - verified May 2012

Condition:   Acute Myeloid Leukemia
Intervention:   Drug: Sorafenib
Sponsors:   Massachusetts General Hospital;   Massachusetts General Hospital;   Dana-Farber Cancer Institute
Recruiting - verified April 2012

Conditions:   Cervical Cancer;   Uterine Cancer;   Vaginal Cancer;   Carcinoma of the Vulva
Intervention:   Procedure: Image-guided brachytherapy
Sponsors:   Dana-Farber Cancer Institute;   Dana-Farber Cancer Institute
Recruiting - verified February 2012

Condition:   Chronic Myelogenous Leukemia
Intervention:   Drug: Arsenic trioxide
Sponsors:   Dana-Farber Cancer Institute;   Beth Israel Deaconess Medical Center;   National Institutes of Health (NIH);   Cephalon
Recruiting - verified March 2012

Condition:   Gastrointestinal Stromal Tumor (GIST)
Intervention:   Drug: Pazopanib
Sponsors:   Stanford University;   Kristen Ganjoo;   GlaxoSmithKline
Recruiting - verified December 2011

Conditions:   Prostate Cancer;   Pancreatic Cancer;   Melanoma;   Renal Cell Carcinoma;   Ovarian Cancer;   Colorectal Cancer;   Gastric Cancer;   Bladder Cancer;   Non-small Cell Lung Cancer;   Glioblastoma
Intervention:   Biological: MGA271
Sponsors:   MacroGenics;   MacroGenics
Recruiting - verified December 2011

Condition:   Metastatic Non-Small Cell Lung Cancer
Interventions:   Drug: ARQ 197 plus erlotinib;   Drug: Pemetrexed, docetaxel or gemcitabine
Sponsors:   ArQule;   ArQule
Recruiting - verified January 2012

Condition:   Breast Cancer
Intervention:   Device: NIR Imaging with FLARE and Mini-FLARE Imaging System
Sponsors:   Beth Israel Deaconess Medical Center;   Beth Israel Deaconess Medical Center;   Brigham and Women's Hospital;   Dana-Farber Cancer Institute
Recruiting - verified February 2012

Condition:   Sarcoma, Alveolar Soft Part
Interventions:   Drug: Cediranib;   Drug: Sunitinib
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified March 2012

Conditions:   Cachexia;   Non-Small Cell Lung Cancer
Interventions:   Drug: Anamorelin HCl;   Drug: Placebo
Sponsors:   Helsinn Therapeutics (U.S.), Inc;   Helsinn Therapeutics (U.S.), Inc
Recruiting - verified May 2012

Conditions:   Cachexia;   Non-Small Cell Lung Cancer
Interventions:   Drug: Anamorelin HCl;   Drug: Placebo
Sponsors:   Helsinn Therapeutics (U.S.), Inc;   Helsinn Therapeutics (U.S.), Inc
Recruiting - verified May 2012

Conditions:   Arthralgia;   Breast Cancer;   Pain
Interventions:   Dietary Supplement: omega-3 fatty acid;   Other: placebo
Sponsors:   National Cancer Institute (NCI);   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Conditions:   Brain and Central Nervous System Tumors;   Cognitive/Functional Effects;   Fatigue;   Neurotoxicity;   Psychosocial Effects of Cancer and Its Treatment
Interventions:   Drug: modafinil;   Other: placebo
Sponsors:   National Cancer Institute (NCI);   University of South Florida;   National Cancer Institute (NCI)
Recruiting - verified September 2011

Conditions:   Metastatic ER+ Her2- Breast Cancer;   Postmenopausal
Interventions:   Drug: Exemestane;   Drug: Abiraterone acetate + Prednisone/ Prednisolone + Exemestane;   Drug: Abiraterone acetate + Prednisone or Prednisolone
Sponsors:   Janssen Research & Development, LLC;   Janssen Research & Development, LLC
Recruiting - verified May 2012

Condition:   Polycystic Ovary Syndrome
Intervention:   Drug: Metformin ER
Sponsors:   Massachusetts General Hospital;   Massachusetts General Hospital;   American Diabetes Association
Recruiting - verified July 2011

Condition:   Pulmonary Coin Lesion
Intervention:   Procedure: Lung biopsy using Always On EM Tip Tracked Device
Sponsors:   Veran Medical Technologies;   Veran Medical Technologies;   Institute for Quality Resource Management
Recruiting - verified July 2011

Condition:   Prostate Cancer
Interventions:   Drug: Abiraterone acetate;   Drug: Dutasteride;   Drug: Prednisone
Sponsors:   Dana-Farber Cancer Institute;   Mary-Ellen Taplin, MD
Recruiting - verified February 2012

Condition:   Multiple Myeloma
Intervention:   Drug: MLN9708 + Lenalidomide + Dexamethasone
Sponsors:   Millennium Pharmaceuticals, Inc.;   Millennium Pharmaceuticals, Inc.
Recruiting - verified May 2012

Condition:   Advanced Solid Tumor
Intervention:   Drug: MEK inhibitor MSC1936369B and Temsirolimus
Sponsors:   EMD Serono;   EMD Serono
Recruiting - verified April 2012

Condition:   Head and Neck Cancer
Interventions:   Drug: CUDC-101;   Drug: Cisplatin;   Radiation: Radiation Therapy
Sponsors:   Curis, Inc.;   Curis, Inc.
Recruiting - verified May 2012

Condition:   Malignant Melanoma
Intervention:   Drug: vemurafenib
Sponsors:   Hoffmann-La Roche;   Hoffmann-La Roche
Recruiting - verified May 2012

Condition:   Relapsed Multiple Myeloma
Interventions:   Drug: Lenalidomide 15mg;   Drug: Lenalidomide 25mg
Sponsors:   Boston VA Research Institute, Inc.;   Boston VA Research Institute, Inc.;   Celgene Corporation;   Kansas City Veteran Affairs Medical Center;   VA Pittsburgh Healthcare System;   VA Greater Los Angeles Healthcare System;   Michael Debakey Veterans Affairs Medical Center;   Edward Hines Jr. VA Hospital
Recruiting - verified September 2011

Condition:   Prevention of GvHD in Patients With Hematological Malignancies Undergoing AHSCT
Intervention:   Drug: RGI-2001
Sponsors:   Regimmune Inc.;   Regimmune Inc.;   Pacific-Link Regulatory Consulting LLC
Recruiting - verified January 2012

Condition:   Solid Cancers
Intervention:   Drug: MPDL3280A
Sponsors:   Genentech;   Genentech
Recruiting - verified March 2012

Conditions:   Glioblastoma;   Gliosarcoma;   Anaplastic Astrocytoma;   Anaplastic Oligodendroglioma;   Anaplastic Oligoastrocytoma
Intervention:   Drug: BIBF 1120
Sponsors:   Dana-Farber Cancer Institute;   Patrick Y. Wen, MD;   Boehringer Ingelheim Pharmaceuticals;   Wake Forest University Baptist Medical Center;   Dartmouth-Hitchcock Medical Center;   University of Virginia;   Massachusetts General Hospital
Not yet recruiting - verified December 2011

Condition:   Colorectal Cancer
Interventions:   Drug: bevacizumab;   Drug: FOLFIRI regimen;   Drug: mFOLFOX6
Sponsors:   Genentech;   Genentech
Recruiting - verified December 2011

Condition:   Islet Cell Tumor
Interventions:   Drug: Everolimus;   Drug: Pasireotide + Everolimus
Sponsors:   Novartis;   Novartis Pharmaceuticals
Recruiting - verified April 2012

Condition:   Prostate Cancer
Interventions:   Radiation: radiation therapy;   Radiation: selective external radiation therapy
Sponsors:   National Cancer Institute (NCI);   Radiation Therapy Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Conditions:   Brain Edema;   Brain Tumor
Intervention:   Drug: XERECEPT (corticorelin acetate injection)
Sponsors:   Celtic Pharma Development Services;   Celtic Pharma Development Services
Recruiting - verified June 2011

Conditions:   Fallopian Tube Cancer;   Ovarian Cancer;   Primary Peritoneal Cavity Cancer
Interventions:   Biological: filgrastim;   Drug: carboplatin;   Drug: paclitaxel;   Other: pharmacological study;   Other: questionnaire administration;   Procedure: assessment of therapy complications;   Procedure: quality-of-life assessment
Sponsors:   National Cancer Institute (NCI);   Gynecologic Oncology Group
Recruiting - verified May 2012

Condition:   Cancer
Interventions:   Drug: carboplatin;   Drug: paclitaxel;   Drug: veliparib;   Other: laboratory biomarker analysis;   Other: pharmacological study
Sponsors:   National Cancer Institute (NCI);   University of Pittsburgh;   National Cancer Institute (NCI)
Recruiting - verified January 2012

Conditions:   Crohn's Disease;   IBD;   Colitis;   Inflammatory Bowel Disease
Interventions:   Drug: Group 2 ustekinumab 130 mg;   Drug: Group 3: ustekinumab approximately 6 mg/kg;   Drug: Group 1: Placebo
Sponsors:   Johnson & Johnson Pharmaceutical Research & Development, L.L.C.;   Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified April 2012

Conditions:   Bacterial Infection;   Leukemia;   Musculoskeletal Complications;   Neutropenia
Interventions:   Drug: levofloxacin;   Procedure: standard follow-up care
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Hematologic Neoplasms
Intervention:  
Sponsors:   Center for International Blood and Marrow Transplant Research;   Center for International Blood and Marrow Transplant Research;   National Marrow Donor Program
Recruiting - verified June 2011

Condition:   Solid Cancers
Interventions:   Drug: docetaxel;   Drug: GDC-0068;   Drug: mFOLFOX6
Sponsors:   Genentech;   Genentech
Recruiting - verified April 2012

Conditions:   Advanced Solid Tumors,;   Selected Solid Tumors
Intervention:   Drug: BKM120 + MEK162
Sponsors:   Novartis;   Novartis Pharmaceuticals
Recruiting - verified May 2012

Condition:   Metastatic Pancreatic Adenocarcinoma
Interventions:   Drug: ON 01910.Na;   Drug: Gemcitabine;   Drug: Gemcitabine
Sponsors:   Onconova Therapeutics, Inc.;   Onconova Therapeutics, Inc.;   Academic Oncology Gastrointestinal Cancer Consortium (AGICC)
Recruiting - verified March 2012

Condition:   Breast Cancer
Interventions:   Drug: pertuzumab;   Drug: placebo;   Drug: trastuzumab [Herceptin];   Drug: Chemotherapy
Sponsors:   Hoffmann-La Roche;   Hoffmann-La Roche;   Breast International Group;   Genentech
Recruiting - verified February 2012

Condition:   Lung Cancer, Non-Small Cell
Interventions:   Drug: GSK1120212;   Drug: docetaxel
Sponsors:   GlaxoSmithKline;   GlaxoSmithKline
Recruiting - verified May 2012

Condition:   Neuroendocrine Tumors
Intervention:   Drug: Pasireotide LAR
Sponsors:   Novartis;   Novartis Pharmaceuticals
Recruiting - verified April 2012

Condition:   Tumor, Solid
Intervention:   Drug: SCH 900353
Sponsors:   Schering-Plough;   Schering-Plough
Recruiting - verified May 2012

Condition:   Solid Tumors
Interventions:   Drug: SAR245408 (XL147);   Drug: MSC1936369B
Sponsors:   Sanofi-Aventis;   Sanofi-Aventis
Recruiting - verified April 2012

Conditions:   Muscle Wasting;   Non Small Cell Lung Cancer
Interventions:   Drug: GTx-024;   Drug: placebo
Sponsors:   GTx;   GTx;   Harrison Clinical Research
Recruiting - verified May 2012

Conditions:   Muscle Wasting;   Non-Small Cell Lung Cancer
Interventions:   Drug: GTx-024;   Drug: placebo
Sponsors:   GTx;   GTx;   Harrison Clinical Research
Recruiting - verified May 2012

Condition:   Renal Cell Carcinoma
Interventions:   Drug: BMS-936558 (Anti-PD-1);   Drug: BMS-936558 (Anti-PD-1);   Drug: BMS-936558 (Anti-PD-1)
Sponsors:   Bristol-Myers Squibb;   Bristol-Myers Squibb;   Ono Pharma
Recruiting - verified February 2012

Conditions:   Low Grade Gliomas;   Protoplasmic Astrocytomas;   Fibrillary Astrocytomas;   Gemistocytic Astrocytomas;   Oligoastrocytomas;   Oligodendrogliomas;   Other WHO Grade II/IV Gliomas
Intervention:   Radiation: Proton radiation
Sponsors:   Massachusetts General Hospital;   Massachusetts General Hospital;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Non-Small Cell Lung Cancer
Interventions:   Drug: bevacizumab [Avastin];   Drug: Standard of care treatment
Sponsors:   Hoffmann-La Roche;   Hoffmann-La Roche
Recruiting - verified May 2012

Conditions:   Hematological Malignancies;   Certain Lysosomal Storage and Peroxisomal Enzyme Deficiency Disorders;   Hurler Syndrome (MPS I);   Krabbe Disease (Globoid Leukodystrophy);   X-linked Adrenoleukodystrophy;   Primary Immunodeficiency Diseases;   Bone Marrow Failure;   Beta-thalassemia
Intervention:   Drug: A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs)
Sponsors:   Center for International Blood and Marrow Transplant Research;   Center for International Blood and Marrow Transplant Research;   National Marrow Donor Program
Recruiting - verified April 2012

Condition:   Leukemia
Interventions:   Drug: Dasatinib;   Drug: BMS-833923
Sponsors:   Bristol-Myers Squibb;   Bristol-Myers Squibb
Recruiting - verified November 2011

Condition:   Breast Cancer
Interventions:   Radiation: 3-dimensional conformal radiation therapy;   Radiation: accelerated radiation therapy;   Radiation: hypofractionated radiation therapy;   Radiation: intensity-modulated radiation therapy;   Radiation: whole breast irradiation
Sponsors:   National Cancer Institute (NCI);   Radiation Therapy Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Multiple Myeloma
Interventions:   Biological: Anti-CXCR4 (BMS-936564);   Biological: Lenalidomide;   Biological: Dexamethasone;   Biological: Anti-CXCR4 (BMS-936564);   Biological: Bortezomib;   Biological: Dexamethasone
Sponsors:   Bristol-Myers Squibb;   Bristol-Myers Squibb
Recruiting - verified August 2011

Conditions:   Melanoma;   Breast Neoplasms;   Lobular Carcinoma
Intervention:   Drug: LGK974
Sponsors:   Novartis;   Novartis Pharmaceuticals
Recruiting - verified April 2012

Conditions:   B Cell Non-Hodgkin's Lymphoma;   Chronic Lymphocytic Leukemia;   Waldenstrom Macroglobulinemia
Intervention:   Drug: AVL-292
Sponsors:   Avila Therapeutics;   Avila Therapeutics;   The Leukemia and Lymphoma Society
Recruiting - verified May 2011

Condition:   Renal Cell Carcinoma
Interventions:   Biological: BMS-936558;   Biological: BMS-936558;   Biological: BMS-936558
Sponsors:   Bristol-Myers Squibb;   Bristol-Myers Squibb;   Ono Pharma
Recruiting - verified February 2012

Condition:   Acute Lymphocytic Leukemia
Intervention:   Drug: Inotuzumab Ozogamicin
Sponsors:   Pfizer;   Pfizer;   UCB, Inc.
Recruiting - verified May 2012

Conditions:   Brain and Central Nervous System Tumors;   Nausea and Vomiting;   Unspecified Childhood Solid Tumor, Protocol Specific
Interventions:   Procedure: acupressure therapy;   Procedure: sham intervention
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified October 2011

Condition:   Urothelial Carcinoma
Interventions:   Biological: DN24-02;   Other: Standard of Care
Sponsors:   Dendreon;   Dendreon
Recruiting - verified May 2012

Condition:   Recurrent Glioblastoma
Intervention:   Drug: PLX3397
Sponsors:   Plexxikon;   Plexxikon
Recruiting - verified May 2012

Condition:   Acute Myeloid Leukemia
Interventions:   Drug: PLX3397;   Drug: PLX3397
Sponsors:   Plexxikon;   Plexxikon
Recruiting - verified May 2012

Condition:   Adenocarcinoma of the Rectum
Intervention:   Procedure: Transanal endoscopic surgery
Sponsors:   Massachusetts General Hospital;   Massachusetts General Hospital;   Department of Defense
Recruiting - verified December 2011

Condition:   Melanoma
Intervention:   Drug: STA-9090
Sponsors:   Dana-Farber Cancer Institute;   Dana-Farber Cancer Institute;   Synta Pharmaceuticals Corp.
Recruiting - verified March 2012

Condition:   Invasive Breast Cancer
Intervention:   Radiation: Proton Radiation
Sponsors:   Massachusetts General Hospital;   Massachusetts General Hospital
Recruiting - verified April 2011

Conditions:   Chordoma of Spine;   Chordoma of Sacrum;   Chordoma of Base of Skull;   Chondrosarcoma of the Spine;   Chondrosarcoma of the Sacrum
Intervention:   Radiation: High Dose Intensity Modulated Proton Radiation
Sponsors:   Massachusetts General Hospital;   Massachusetts General Hospital;   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
Not yet recruiting - verified May 2012

Conditions:   Locally Advanced Solid Tumor;   Metastatic Solid Tumor;   Breast Cancer;   Non Small Cell Lung Cancer;   Melanoma;   Colorectal Cancer
Intervention:   Drug: MSC1936369B and SAR245409
Sponsors:   EMD Serono;   EMD Serono;   Sanofi
Recruiting - verified April 2012

Conditions:   Autoimmune Diseases;   Systemic Inflammatory Process;   Knee Pain Chronic;   Osteoarthritis;   Rheumatoid Arthritis
Interventions:   Drug: Fish Oil;   Drug: Vitamin D;   Other: placebo pill
Sponsors:   Brigham and Women's Hospital;   Brigham and Women's Hospital;   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Recruiting - verified May 2012

Condition:   Advanced Liposarcoma or Leiomyosarcoma
Interventions:   Drug: Trabectedin;   Drug: Dacarbazine
Sponsors:   Janssen Research & Development, LLC;   Janssen Research & Development, LLC;   Pharma Mar, S.A.U.
Recruiting - verified May 2012

Condition:   Lung Cancer
Interventions:   Procedure: therapeutic conventional surgery;   Radiation: iodine I 125;   Radiation: stereotactic body radiation therapy
Sponsors:   National Cancer Institute (NCI);   American College of Surgeons;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Conditions:   Castration-resistant Prostate Cancer,;   Metastatic Breast Cancer
Intervention:   Drug: LFA102
Sponsors:   Novartis;   Novartis Pharmaceuticals
Recruiting - verified May 2012

Condition:   Ovarian Cancer
Intervention:   Drug: DMUC5754A
Sponsors:   Genentech;   Genentech
Recruiting - verified July 2011

Condition:   Glioblastoma
Interventions:   Drug: BKM120;   Procedure: Surgery
Sponsors:   Dana-Farber Cancer Institute;   Patrick Y. Wen, MD;   Brigham and Women's Hospital;   Massachusetts General Hospital;   Novartis Pharmaceuticals;   M.D. Anderson Cancer Center;   Memorial Sloan-Kettering Cancer Center;   University of California, San Francisco;   University of California, Los Angeles
Recruiting - verified February 2012

Conditions:   Pain;   Advanced Cancer
Intervention:   Drug: Sativex®
Sponsors:   GW Pharmaceuticals Ltd.;   GW Pharmaceuticals Ltd.;   Otsuka Pharmaceutical Development & Commercialization, Inc.
Recruiting - verified April 2011

Conditions:   Lymphoblastic Leukemia, Acute T-cell;   Precursor T-Cell Lymphoblastic Lymphoma
Intervention:   Drug: BMS-906024
Sponsors:   Bristol-Myers Squibb;   Bristol-Myers Squibb
Recruiting - verified February 2012

Condition:   Leukemia, Myelocytic, Acute
Interventions:   Drug: Fludarabine and Busulfan (Flu/Bu);   Drug: Fludarabine and Melphalan (Flu/Mel);   Drug: Busulfan and Fludarabine (Bu/Flu);   Drug: Busulfan and Cyclophosphamide (Bu/Cy);   Drug: Cyclophosphamide and Total Body Irradiation (Cy/TBI)
Sponsors:   National Heart, Lung, and Blood Institute (NHLBI);   National Heart, Lung, and Blood Institute (NHLBI);   National Cancer Institute (NCI);   Blood and Marrow Transplant Clinical Trials Network
Recruiting - verified March 2012

Condition:   Chemotherapy-Induced Nausea and Vomiting
Interventions:   Drug: Netupitant and Palonosetron;   Drug: Palonosetron
Sponsors:   Helsinn Healthcare SA;   Helsinn Healthcare SA;   Parexel
Recruiting - verified December 2011

Condition:   Multiple Myeloma
Interventions:   Drug: Lenalidomide;   Drug: Dexamethasone;   Drug: Dexamethasone;   Drug: Dexamethasone;   Drug: Dexamethasone;   Biological: Elotuzumab (BMS-901608; HuLuc63);   Biological: Elotuzumab (BMS-901608; HuLuc63)
Sponsors:   Bristol-Myers Squibb;   Bristol-Myers Squibb;   Abbott Biotherapeutics Corp.
Recruiting - verified October 2011

Conditions:   Non-Small Cell Lung Cancer;   Cancer
Intervention:   Drug: GSK2118436
Sponsors:   GlaxoSmithKline;   GlaxoSmithKline
Recruiting - verified May 2012

Condition:   Hepatocellular Carcinoma
Interventions:   Device: HepaSphere/QuadraSphere Microspheres;   Procedure: PVA, lipiodol, doxorubicin
Sponsors:   Merit Medical Systems, Inc.;   Merit Medical Systems, Inc.
Recruiting - verified January 2012

Condition:   Ovarian Cancer Recurrent
Interventions:   Drug: Ombrabulin (AVE8062);   Drug: Placebo;   Drug: Paclitaxel;   Drug: Carboplatin
Sponsors:   Sanofi-Aventis;   Sanofi-Aventis
Recruiting - verified May 2012

Condition:   Colorectal Cancer
Interventions:   Behavioral: Exercise training;   Drug: Exercise training plus metformin;   Drug: Metformin;   Other: Educational information
Sponsors:   Dana-Farber Cancer Institute;   Dana-Farber Cancer Institute
Recruiting - verified February 2012

Condition:   Breast Cancer
Interventions:   Behavioral: reminder letter;   Behavioral: reminder call;   Behavioral: Counselor Call;   Behavioral: Booster reminder;   Behavioral: Booster reminder;   Behavioral: Booster reminder
Sponsors:   University of Massachusetts, Worcester;   University of Massachusetts, Worcester;   Reliant Medical Group;   Fallon Community Health Plan;   National Cancer Institute (NCI)
Recruiting - verified April 2012

Conditions:   Multiple Myeloma;   Renal Insufficiency
Interventions:   Drug: BHQ880;   Drug: BHQ990
Sponsors:   Novartis;   Novartis Pharmaceuticals
Recruiting - verified May 2012

Condition:   Melanoma
Intervention:   Drug: LGX818
Sponsors:   Novartis;   Novartis Pharmaceuticals
Recruiting - verified April 2012

Condition:   Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck
Interventions:   Drug: E7050;   Drug: Cetuximab
Sponsors:   Eisai Inc.;   Eisai Inc.;   PharmaBio Development Inc.
Recruiting - verified April 2012

Condition:   Neuroblastoma
Interventions:   Biological: hu14.18-IL2 fusion protein;   Biological: sargramostim;   Drug: isotretinoin;   Other: laboratory biomarker analysis
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Conditions:   Unspecified Adult Solid Tumor, Protocol Specific;   Solid Tumor
Intervention:   Drug: BEZ235 + MEK162
Sponsors:   Novartis;   Novartis Pharmaceuticals
Recruiting - verified April 2012

Conditions:   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   B Chronic Lymphocytic Leukemia
Interventions:   Drug: Lenalidomide;   Drug: Bendamustine;   Drug: Rituximab
Sponsors:   Massachusetts General Hospital;   Massachusetts General Hospital;   Dana-Farber Cancer Institute
Recruiting - verified February 2012

Conditions:   High Grade Glioma: Glioblastoma (GBM);   High Grade Glioma: Gliosarcoma;   Anaplastic Astrocytoma (AA);   Anaplastic Oligodendroglioma (AO);   Mixed Anaplastic Oligoastrocytoma (AOA)
Interventions:   Drug: Plerixafor;   Drug: Plerixafor;   Drug: Bevacizumab;   Drug: Plerixafor;   Procedure: Surgery
Sponsors:   Dana-Farber Cancer Institute;   Patrick Y. Wen, MD;   Dana-Farber Cancer Institute;   Brigham and Women's Hospital;   Massachusetts General Hospital;   Genzyme
Recruiting - verified February 2012

Conditions:   Chronic Lymphocytic Leukemia;   Non-Hodgkin's Lymphoma
Intervention:   Drug: ABT-199
Sponsors:   Abbott;   Abbott;   Genentech
Recruiting - verified March 2012

Condition:   Prostate Cancer Metastatic
Interventions:   Biological: PROSTVAC-V/F-TRICOM + GM-CSF;   Biological: PROSTVAC-V/F-TRICOM + GM-CSF placebo;   Biological: Placebo
Sponsors:   BN ImmunoTherapeutics;   BN ImmunoTherapeutics
Recruiting - verified January 2012

Condition:   Prostate Cancer
Interventions:   Dietary Supplement: Vitamin D and Genistein;   Other: Placebo
Sponsors:   University of Wisconsin, Madison;   University of Wisconsin, Madison;   University of Alabama at Birmingham;   University of Rochester;   University of Minnesota - Clinical and Translational Science Institute;   Lahey Clinic;   Urology San Antonio
Recruiting - verified January 2012

Condition:   Soft Tissue Sarcoma
Interventions:   Drug: Eribulin mesylate 1.4 mg/m2 intravenous;   Drug: Dacarbazine of 850 mg/m2, or 1,000 mg/m2, or 1,200 mg/m2 IV
Sponsors:   Eisai Inc.;   Eisai Inc.
Recruiting - verified May 2012

Condition:   Basal Cell Carcinoma
Intervention:   Drug: LDE225
Sponsors:   Novartis;   Novartis Pharmaceuticals
Recruiting - verified April 2012

Condition:   Glioblastoma
Intervention:   Drug: bosutinib
Sponsors:   Massachusetts General Hospital;   Massachusetts General Hospital;   Dana-Farber Cancer Institute;   Brigham and Women's Hospital;   Pfizer
Recruiting - verified April 2012

Conditions:   Lymphoblastic Leukemia, Acute, Childhood;   Myelogenous Leukemia, Acute, Childhood;   Hodgkin's Disease;   Non-Hodgkin's Lymphoma
Interventions:   Drug: Panobinostat;   Drug: Cytarabine;   Drug: Panobinostat
Sponsors:   Therapeutic Advances in Childhood Leukemia Consortium;   Therapeutic Advances in Childhood Leukemia Consortium;   Novartis
Recruiting - verified November 2011

Conditions:   Leukemia;   Lymphoma;   Myelodysplastic Syndrome
Intervention:   Drug: Bortezomib, Tacrolimus, Methotrexate
Sponsors:   Dana-Farber Cancer Institute;   Dana-Farber Cancer Institute
Recruiting - verified May 2011

Condition:   Gastrointestinal Stromal Tumor (GIST)
Intervention:   Biological: IMC-3G3
Sponsors:   ImClone LLC;   ImClone LLC
Recruiting - verified March 2012

Conditions:   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Hepatosplenic T-cell Lymphoma;   Peripheral T-cell Lymphoma
Interventions:   Drug: prednisone;   Drug: cyclophosphamide;   Drug: etoposide;   Drug: vincristine sulfate;   Drug: pralatrexate;   Other: laboratory biomarker analysis;   Genetic: comparative genomic hybridization;   Genetic: gene expression analysis;   Genetic: nucleic acid sequencing;   Genetic: mutation analysis;   Other: immunohistochemistry staining method;   Genetic: microarray analysis;   Genetic: RNA analysis
Sponsors:   University of Nebraska;   University of Nebraska;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Conditions:   Diffuse Large B-cell Lymphoma;   de Novo DLBCL;   DLBCL Transformed From Indolent Lymphoma;   Follicular Grade 3 Lymphoma
Interventions:   Drug: Pixantrone + Rituximab;   Drug: Gemcitabine + Rituximab
Sponsors:   Cell Therapeutics;   Cell Therapeutics
Recruiting - verified May 2012

Condition:   Thyroid Cancer
Interventions:   Drug: lenvatinib 24 mg administered orally, once a day;   Drug: Placebo 24mg administered orally, once a day
Sponsors:   Eisai Inc.;   Eisai Inc.
Recruiting - verified April 2012

Condition:   Prostate Cancer
Intervention:   Other: Questionnaire
Sponsors:   Dana-Farber Cancer Institute;   Beth Israel Deaconess Medical Center;   Brigham and Women's Hospital;   The Cleveland Clinic;   Johns Hopkins University;   University of California, San Francisco;   University of Michigan;   Vanderbilt University;   Washington University School of Medicine
Recruiting - verified May 2012

Conditions:   Oropharyngeal Cancer;   Human Papillomavirus
Intervention:  
Sponsors:   Johns Hopkins Bloomberg School of Public Health;   Johns Hopkins Bloomberg School of Public Health;   Mount Sinai School of Medicine;   Oregon Health and Science University;   Dana-Farber Cancer Institute;   Johns Hopkins Hospital (JHH)
Recruiting - verified May 2012

Condition:   BRAF or NRAS Mutant Metastatic Melanoma
Intervention:   Drug: MEK162
Sponsors:   Novartis;   Novartis Pharmaceuticals
Recruiting - verified April 2012

Conditions:   Prostate Cancer;   Prostatic Neoplasm
Intervention:   Drug: abiraterone acetate in combination with prednisone
Sponsors:   Janssen Biotech, Inc.;   Janssen Biotech, Inc.
Recruiting - verified May 2012

Condition:   Neoplasms
Intervention:   Behavioral: Yoga
Sponsors:   Department of Veterans Affairs;   Department of Veterans Affairs;   Wake Forest University
Recruiting - verified February 2012

Condition:   Endometrial Cancer
Interventions:   Drug: Akt inhibitor MK2206;   Other: laboratory biomarker analysis
Sponsors:   National Cancer Institute (NCI);   Dana-Farber Cancer Institute;   National Cancer Institute (NCI)
Recruiting - verified October 2011

Conditions:   Fallopian Tube Cancer;   Ovarian Cancer;   Primary Peritoneal Cavity Cancer
Interventions:   Biological: bevacizumab;   Drug: fosbretabulin tromethamine
Sponsors:   National Cancer Institute (NCI);   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Conventional Chondrosarcoma
Interventions:   Drug: IPI-926;   Drug: Placebo Arm
Sponsors:   Infinity Pharmaceuticals, Inc.;   Infinity Pharmaceuticals, Inc.
Recruiting - verified May 2012

Condition:   Breast Cancer
Intervention:   Drug: MM-302
Sponsors:   Merrimack Pharmaceuticals;   Merrimack Pharmaceuticals
Recruiting - verified November 2011

Conditions:   Head and Neck Cancer;   Precancerous Condition
Interventions:   Biological: cetuximab;   Drug: cisplatin
Sponsors:   National Cancer Institute (NCI);   Radiation Therapy Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Conditions:   Fungal Infection;   Leukemia;   Neutropenia
Interventions:   Drug: caspofungin acetate;   Drug: fluconazole
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Multiple Myeloma
Intervention:   Drug: ACY-1215
Sponsors:   Acetylon Pharmaceuticals Incorporated;   Acetylon Pharmaceuticals Incorporated;   The Leukemia and Lymphoma Society
Recruiting - verified April 2012

Condition:   Prostate CA
Interventions:   Drug: Dexamethasone;   Procedure: TAP block
Sponsors:   Steward St. Elizabeth's Medical Center of Boston, Inc.;   Steward St. Elizabeth's Medical Center of Boston, Inc.
Recruiting - verified February 2011

Condition:   Solid Cancers
Interventions:   Drug: bevacizumab;   Drug: carboplatin;   Drug: GDC-0980;   Drug: paclitaxel
Sponsors:   Genentech;   Genentech
Recruiting - verified February 2012

Condition:   Breast Cancer
Intervention:   Drug: rosuvastatin
Sponsors:   Dana-Farber Cancer Institute;   Beth Israel Deaconess Medical Center;   Dana-Farber Cancer Institute;   Massachusetts General Hospital;   National Institutes of Health (NIH)
Recruiting - verified February 2012

Condition:   Solid Cancers
Intervention:   Drug: GDC-0032
Sponsors:   Genentech;   Genentech
Recruiting - verified January 2012

Condition:   Non-small Cell Lung Cancer
Interventions:   Drug: BKM120 or Docetaxel;   Drug: BKM120 or Docetaxel or Pemetrexed
Sponsors:   Novartis;   Novartis Pharmaceuticals
Recruiting - verified May 2012

Conditions:   Brain Tumor;   Spinal Tumor;   Glial Tumour of Brain;   Ependymal Tumour of Brain;   Spinal Cord Ependymoma;   Anaplastic Ependymoma
Interventions:   Drug: Bevacizumab;   Drug: Carboplatin
Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center;   CERN Foundation - Collaborative Ependymoma Research Network
Recruiting - verified February 2012

Condition:   Cancer, Solid Tumor
Interventions:   Drug: MK-3475 1 mg/kg;   Drug: MK-3475 3 mg/kg;   Drug: MK-3475 10 mg/kg;   Drug: MK-3475 MEL;   Drug: MK-3475 NSCLC
Sponsors:   Schering-Plough;   Schering-Plough
Recruiting - verified April 2012

Condition:   Gastrointestinal Stromal Tumor (GIST)
Intervention:   Drug: AT13387 and Imatinib
Sponsors:   Astex Pharmaceuticals;   Astex Pharmaceuticals
Recruiting - verified March 2012

Conditions:   Solid Tumors;   Relapsed/Refractory Sarcomas
Intervention:   Drug: Vorinostat and Etoposide
Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center;   Merck;   Phoenix Children's Hospital;   Penn State Children's Hospital;   Johns Hopkins University;   Sidney Kimmel Comprehensive Cancer Center;   Children's Hospital Colorado;   University of Florida;   Alberta Children's Hospital;   M.D. Anderson Cancer Center;   Dana-Farber Cancer Institute;   Children's Mercy Hospital & Clinics;   All Children's Hospital;   Arnold Palmer Hospital for Children/MD Anderson Cancer Center Orlando
Recruiting - verified February 2012

Condition:   Colorectal Cancer
Interventions:   Biological: Imprime PGG + cetuximab;   Drug: Cetuximab
Sponsors:   Biothera;   Biothera
Recruiting - verified April 2012

Condition:   Renal Cell Carcinoma
Intervention:   Drug: Tivozanib
Sponsors:   AVEO Pharmaceuticals, Inc.;   AVEO Pharmaceuticals, Inc.
Recruiting - verified September 2011

Condition:   Chronic Lymphocytic Leukemia
Interventions:   Drug: bendamustine;   Drug: cyclophosphamide;   Drug: Fludarabine;   Drug: RO5072759
Sponsors:   Genentech;   Genentech
Recruiting - verified March 2012

Conditions:   Brain Tumor;   Low Grade Glioma;   Astrocytoma;   Ependymoma;   Ganglioglioma
Intervention:   Radiation: Proton radiotherapy
Sponsors:   Massachusetts General Hospital;   Massachusetts General Hospital;   Dana-Farber Cancer Institute
Recruiting - verified September 2011

Conditions:   Acute Lymphoblastic Leukemia;   Acute Myeloid Leukemia;   Chronic Myeloid Leukemia;   Myelodysplasia
Intervention:   Biological: human myeloid progenitor cells
Sponsors:   Cellerant Therapeutics;   Cellerant Therapeutics;   Department of Health and Human Services
Recruiting - verified May 2012

Condition:   Neoplasms
Intervention:   Biological: IMC-3C5
Sponsors:   ImClone LLC;   ImClone LLC
Recruiting - verified February 2012

Conditions:   GVHD;   Adult Acute Myeloid Leukemia;   Acute Lymphoid Leukemia;   Myelodysplastic Syndrome
Interventions:   Biological: Anti-human-T-lymphocyte Immune Globulin, Rabbit;   Biological: Placebo
Sponsors:   Fresenius Biotech GmbH;   Fresenius Biotech GmbH;   Fresenius Biotech North America
Recruiting - verified April 2012

Condition:   Neoplasms
Intervention:   Drug: RO5185426
Sponsors:   Hoffmann-La Roche;   Hoffmann-La Roche
Recruiting - verified May 2012

Conditions:   Ovarian Cancer;   Fallopian Tube Cancer;   Primary Peritoneal Cancer
Intervention:   Drug: MK-2206
Sponsors:   Dana-Farber Cancer Institute;   Dana-Farber Cancer Institute
Recruiting - verified February 2012

Condition:   Oral Mucositis
Interventions:   Device: MuGard;   Device: Control Rinse
Sponsors:   Access Pharmaceuticals, Inc.;   Access Pharmaceuticals, Inc.
Recruiting - verified April 2012

Condition:   Lymphoma, Non-Hodgkin
Interventions:   Biological: Ofatumumab;   Drug: Bendamustine
Sponsors:   GlaxoSmithKline;   GlaxoSmithKline
Recruiting - verified December 2011

Condition:   Tumors Characterized by Genetic Abnormalities of ALK
Intervention:   Drug: LDK378
Sponsors:   Novartis;   Novartis Pharmaceuticals
Recruiting - verified April 2012

Conditions:   Bladder Cancer;   Extrahepatic Bile Duct Cancer;   Gallbladder Cancer;   Liver Cancer;   Lung Cancer;   Pancreatic Cancer;   Transitional Cell Cancer of the Renal Pelvis and Ureter
Interventions:   Drug: cisplatin;   Drug: gemcitabine hydrochloride;   Drug: veliparib;   Other: laboratory biomarker analysis;   Other: pharmacological study
Sponsors:   National Cancer Institute (NCI);   University of Pittsburgh;   National Cancer Institute (NCI)
Recruiting - verified August 2011

Condition:   Adenocarcinoma of the Rectum
Intervention:   Drug: Midostaurin
Sponsors:   Massachusetts General Hospital;   Massachusetts General Hospital
Recruiting - verified December 2011

Condition:   Smoldering Multiple Myeloma
Intervention:   Drug: BHQ880
Sponsors:   Novartis;   Novartis Pharmaceuticals
Recruiting - verified May 2012

Condition:   Breast Cancer
Interventions:   Drug: Akt inhibitor MK2206;   Drug: lapatinib ditosylate;   Genetic: cytogenetic analysis;   Genetic: gene expression analysis;   Other: laboratory biomarker analysis;   Other: pharmacogenomic studies;   Other: pharmacological study
Sponsors:   National Cancer Institute (NCI);   Barbara Ann Karmanos Cancer Institute;   National Cancer Institute (NCI)
Recruiting - verified July 2011

Condition:   Tuberous Sclerosis Complex
Intervention:   Drug: RAD001
Sponsors:   Children's Hospital Boston;   Mustafa Sahin;   Tuberous Sclerosis Alliance;   Autism Speaks;   Novartis Pharmaceuticals;   Seizure Tracker LLC
Recruiting - verified February 2012

Condition:   Renal Cell Carcinoma
Intervention:   Drug: BKM-120 Bevacizumab
Sponsors:   Dana-Farber Cancer Institute;   Toni Choueiri, MD;   Beth Israel Deaconess Medical Center
Recruiting - verified February 2012

Conditions:   Cognitive/Functional Effects;   Colorectal Cancer;   Neurotoxicity
Interventions:   Biological: bevacizumab;   Drug: capecitabine;   Drug: fluorouracil;   Drug: leucovorin calcium;   Drug: oxaliplatin
Sponsors:   National Cancer Institute (NCI);   North Central Cancer Treatment Group;   National Cancer Institute (NCI);   Cancer and Leukemia Group B
Recruiting - verified February 2012

Condition:   Uterine Fibroid(s)
Intervention:   Device: ExAblate UF V2
Sponsors:   InSightec;   InSightec
Not yet recruiting - verified April 2012

Condition:   Neoplasms
Intervention:   Drug: ZSTK474
Sponsors:   Zenyaku Kogyo Co., Ltd.;   Zenyaku Kogyo Co., Ltd.
Recruiting - verified November 2011

Conditions:   Neoplasms;   Ovarian Neoplasms;   Fallopian Tube Neoplasms;   Primary Peritoneal Neoplasm
Interventions:   Biological: KHK2866;   Drug: Gemcitabine and Carboplatin;   Drug: paclitaxel;   Drug: pegylated liposomal doxorubicin
Sponsors:   Kyowa Hakko Kirin Pharma, Inc.;   Kyowa Hakko Kirin Pharma, Inc.
Recruiting - verified February 2012

Condition:   Breast Cancer
Interventions:   Biological: trastuzumab;   Drug: cyclophosphamide;   Drug: docetaxel;   Drug: doxorubicin hydrochloride;   Drug: paclitaxel
Sponsors:   National Cancer Institute (NCI);   National Surgical Adjuvant Breast and Bowel Project (NSABP);   National Cancer Institute (NCI)
Recruiting - verified February 2012

Condition:   Diffuse Large B Cell Lymphoma
Intervention:   Drug: Panobinostat with Rituximab
Sponsors:   Massachusetts General Hospital;   Massachusetts General Hospital;   Dana-Farber Cancer Institute;   Beth Israel Deaconess Medical Center
Recruiting - verified February 2012

Condition:   Solid Tumors
Intervention:   Drug: GO-203-2c
Sponsors:   Genus Oncology, LLC;   Genus Oncology, LLC
Recruiting - verified January 2012

Condition:   Glioblastoma Multiforme
Interventions:   Biological: ICT-107;   Biological: Placebo DC
Sponsors:   ImmunoCellular Therapeutics, Ltd.;   ImmunoCellular Therapeutics, Ltd.
Recruiting - verified May 2012

Condition:   Pancreatic Cancer
Interventions:   Drug: Hydroxychloroquine;   Drug: Hydroxychloroquine
Sponsors:   Dana-Farber Cancer Institute;   Dana-Farber Cancer Institute;   Brigham and Women's Hospital;   Massachusetts General Hospital
Recruiting - verified March 2012

Conditions:   Brain and Central Nervous System Tumors;   Lymphoma;   Lymphoproliferative Disorder;   Small Intestine Cancer;   Unspecified Childhood Solid Tumor, Protocol Specific
Interventions:   Drug: imetelstat sodium;   Other: laboratory biomarker analysis;   Other: pharmacological study
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Breast Cancer
Interventions:   Drug: anastrozole;   Drug: exemestane;   Drug: letrozole;   Drug: systemic chemotherapy;   Drug: tamoxifen citrate
Sponsors:   National Cancer Institute (NCI);   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified February 2012

Conditions:   Adenocarcinoma of the Prostate;   Hormone-resistant Prostate Cancer;   Recurrent Prostate Cancer;   Stage IV Prostate Cancer
Interventions:   Drug: Hsp90 inhibitor STA-9090;   Other: laboratory biomarker analysis;   Genetic: polymerase chain reaction;   Other: enzyme-linked immunosorbent assay;   Genetic: RNA analysis;   Other: spectrophotometry;   Genetic: reverse transcriptase-polymerase chain reaction;   Genetic: gene expression analysis
Sponsors:   Barbara Ann Karmanos Cancer Institute;   Barbara Ann Karmanos Cancer Institute;   National Cancer Institute (NCI)
Recruiting - verified February 2012

Condition:   Thyroid Cancer
Interventions:   Drug: Everolimus;   Drug: Pasireotide;   Drug: Everolimus and Pasireotide
Sponsors:   Emory University;   Emory University;   Novartis
Recruiting - verified April 2012

Condition:   Metastatic Pancreatic Cancer
Interventions:   Biological: bavituximab;   Drug: Gemcitabine
Sponsors:   Peregrine Pharmaceuticals;   Peregrine Pharmaceuticals
Recruiting - verified May 2012

Condition:   Follicular Lymphoma
Intervention:   Drug: HCD122
Sponsors:   Novartis;   Novartis Pharmaceuticals
Recruiting - verified March 2012

Condition:   Melanoma (Skin)
Interventions:   Biological: ipilimumab;   Biological: recombinant interferon alfa-2b
Sponsors:   National Cancer Institute (NCI);   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Lung Cancer
Intervention:   Other: Nursing Educational Intervention
Sponsors:   Dana-Farber Cancer Institute;   Dana-Farber Cancer Institute
Recruiting - verified December 2010

Condition:   Cervical Cancer
Interventions:   Drug: brivanib alaninate;   Other: laboratory biomarker analysis
Sponsors:   National Cancer Institute (NCI);   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Non-small Cell Lung Cancer
Interventions:   Drug: Carboplatin/Paclitaxel/MEDI-575;   Drug: Carboplatin/Paclitaxel;   Drug: Carboplatin/Paclitaxel/MEDI-575
Sponsors:   MedImmune LLC;   MedImmune LLC
Recruiting - verified May 2012

Conditions:   Anemia;   Carcinoma, Non-Small-Cell Lung;   Carcinoma, Small-Cell Lung;   Bladder Cancer;   Cancer of Head and Neck;   Uterine Cervical Cancer
Interventions:   Drug: ACE-011 - 15 mg;   Drug: ACE-011 - 30 mg;   Drug: ACE-011 - 45 mg
Sponsors:   Celgene Corporation;   Celgene Corporation
Recruiting - verified February 2012

Condition:   Pain
Interventions:   Drug: Sativex®;   Drug: Placebo (GA-0034)
Sponsors:   GW Pharmaceuticals Ltd.;   GW Pharmaceuticals Ltd.;   Otsuka Pharmaceutical Development & Commercialization, Inc.
Recruiting - verified May 2011

Conditions:   Colorectal Neoplasms;   Digestive System Diseases;   Colonic Diseases;   Colorectal Cancer
Intervention:  
Sponsors:   Exact Sciences Corporation;   Exact Sciences Corporation
Recruiting - verified August 2011

Condition:   Breast Cancer
Interventions:   Drug: bevacizumab;   Drug: GDC-0980;   Drug: paclitaxel
Sponsors:   Genentech;   Genentech
Recruiting - verified May 2012

Conditions:   Incurable Metastatic Colorectal Carcinoma;   Incurable Progressive, Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Interventions:   Drug: PX-866 and cetuximab;   Drug: Cetuximab;   Drug: PX-866 and cetuximab;   Drug: Cetuximab
Sponsors:   Oncothyreon Inc.;   Oncothyreon Inc.
Recruiting - verified April 2012

Conditions:   Anal Cancer;   Breast Cancer;   Esophageal Cancer;   Gastric Cancer;   Head and Neck Cancer;   Lung Cancer;   Nonneoplastic Condition;   Ovarian Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions:   Drug: carboplatin;   Drug: paclitaxel;   Drug: vorinostat;   Other: laboratory biomarker analysis;   Other: pharmacological study
Sponsors:   National Cancer Institute (NCI);   AIDS Associated Malignancies Clinical Trials Consortium;   National Cancer Institute (NCI)
Recruiting - verified April 2012

Conditions:   Advanced Malignancy;   Advanced Solid Tumors;   Cancer;   Oncology;   Oncology Patients;   Tumors
Intervention:   Drug: AMG 337
Sponsors:   Amgen;   Amgen
Recruiting - verified July 2011

Condition:   Metastatic Breast Cancer
Interventions:   Drug: BKM120;   Drug: BEZ235;   Drug: Letrozole;   Drug: BKM120
Sponsors:   Vanderbilt-Ingram Cancer Center;   Vanderbilt-Ingram Cancer Center
Recruiting - verified July 2011

Condition:   Chronic Myeloid Leukemia
Intervention:  
Sponsors:   Gruppo Italiano Malattie EMatologiche dell'Adulto;   Gruppo Italiano Malattie EMatologiche dell'Adulto
Recruiting - verified December 2010

Condition:   Advanced Solid Tumors
Intervention:   Drug: ABT-806
Sponsors:   Abbott;   Abbott
Recruiting - verified March 2012

Condition:   Breast Cancer
Interventions:   Procedure: palliative surgery;   Procedure: therapeutic conventional surgery;   Radiation: palliative radiation therapy;   Radiation: radiation therapy
Sponsors:   National Cancer Institute (NCI);   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Advanced Cancer
Intervention:   Behavioral: video decision aid
Sponsors:   Massachusetts General Hospital;   Massachusetts General Hospital
Recruiting - verified January 2012

Condition:   Solid Tumors
Intervention:   Drug: LCL161
Sponsors:   Novartis;   Novartis Pharmaceuticals
Recruiting - verified April 2012

Condition:   Prostate Cancer
Interventions:   Behavioral: telephone-based intervention;   Other: counseling intervention;   Other: educational intervention;   Procedure: therapeutic dietary intervention
Sponsors:   National Cancer Institute (NCI);   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified February 2012

Condition:   Colorectal Cancer
Interventions:   Procedure: Colonoscopy;   Procedure: FIT
Sponsors:   Department of Veterans Affairs;   Department of Veterans Affairs
Not yet recruiting - verified April 2012

Conditions:   Stomach Cancer;   Esophageal Cancer
Interventions:   Biological: Ramucirumab;   Drug: Placebo;   Drug: Oxaliplatin;   Drug: Leucovorin;   Drug: 5-Fluorouracil
Sponsors:   Eli Lilly and Company;   Eli Lilly and Company
Recruiting - verified May 2012

Condition:   Pancreatic Neoplasms
Intervention:   Drug: BAY86-9766+Gemcitabine
Sponsors:   Bayer;   Bayer
Recruiting - verified May 2012

Condition:   Chronic Myeloid Leukemia
Intervention:  
Sponsors:   Bristol-Myers Squibb;   Bristol-Myers Squibb;   ICON Clinical Research
Recruiting - verified May 2012

Conditions:   Advanced Solid Tumor;   Lymphomas
Intervention:   Drug: LEE011
Sponsors:   Novartis;   Novartis Pharmaceuticals
Recruiting - verified April 2012

Condition:   Multiple Myeloma
Interventions:   Drug: Lenalidomide;   Drug: Dexamethasone;   Drug: Dexamethasone (Oral);   Drug: Dexamethasone (IV);   Biological: Elotuzumab (BMS-901608; HuLuc63)
Sponsors:   Bristol-Myers Squibb;   Bristol-Myers Squibb;   Abbott Biotherapeutics Corp.
Recruiting - verified May 2012

Conditions:   Uterine Fibroids;   Polyps
Intervention:   Device: Hysteroscopic Morcellator
Sponsors:   Hologic, Inc.;   Hologic, Inc.
Recruiting - verified September 2011

Conditions:   Follicular Lymphoma;   Marginal Zone Lymphoma;   Small Lymphocytic Lymphoma
Intervention:   Drug: ofatumumab
Sponsors:   Massachusetts General Hospital;   Massachusetts General Hospital;   Dana-Farber Cancer Institute;   Beth Israel Deaconess Medical Center;   GlaxoSmithKline
Recruiting - verified November 2011

Condition:   Leukemia
Interventions:   Drug: cytarabine;   Drug: dasatinib;   Drug: daunorubicin hydrochloride
Sponsors:   National Cancer Institute (NCI);   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Conditions:   Brain and Central Nervous System Tumors;   Kidney Cancer;   Sarcoma
Interventions:   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: ifosfamide;   Drug: topotecan hydrochloride;   Drug: vincristine sulfate
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Conditions:   Brain and Central Nervous System Tumors;   Leukemia;   Lymphoma;   Lymphoproliferative Disorder;   Small Intestine Cancer;   Unspecified Childhood Solid Tumor, Protocol Specific
Interventions:   Drug: Akt inhibitor MK2206;   Other: laboratory biomarker analysis;   Other: pharmacological study
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2012

Conditions:   Islet Cell Tumor;   Pancreatic Cancer
Interventions:   Biological: bevacizumab;   Drug: everolimus;   Drug: octreotide acetate
Sponsors:   National Cancer Institute (NCI);   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Conditions:   Brain Tumor;   Head and Neck Tumor;   Skull Base Tumor
Intervention:   Procedure: PET scan
Sponsors:   Massachusetts General Hospital;   Massachusetts General Hospital;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Conditions:   Carcinoma;   Hepatocellular
Intervention:   Drug: LY2157299
Sponsors:   Eli Lilly and Company;   Eli Lilly and Company
Recruiting - verified May 2012

Condition:   Metastatic Pancreatic Adenocarcinoma
Intervention:   Drug: CO-1.01
Sponsors:   Clovis Oncology, Inc.;   Clovis Oncology, Inc.
Recruiting - verified March 2012

Conditions:   Myelodysplastic Syndromes;   MDS;   RAEB;   Chronic Myelomonocytic Leukemia
Intervention:   Drug: ON 01910.Na
Sponsors:   Onconova Therapeutics, Inc.;   Onconova Therapeutics, Inc.;   The Leukemia and Lymphoma Society
Recruiting - verified April 2012

Condition:   Breast Cancer
Interventions:   Dietary Supplement: vitamin D;   Other: placebo
Sponsors:   National Cancer Institute (NCI);   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Conditions:   Adenocarcinoma of the Pancreas;   Advanced Solid Tumors;   Cancer;   Cancer of Pancreas;   Cancer of the Pancreas;   Metastases;   Metastatic Cancer;   Metastatic Pancreatic Cancer;   Pancreas Cancer;   Pancreatic Cancer;   Bone Metastases;   Endocrine Cancer;   Oncology;   Oncology Patients;   Solid Tumors;   Advanced Malignancy
Interventions:   Drug: AMG 479;   Drug: Placebo;   Drug: AMG 479;   Drug: gemcitabine
Sponsors:   Amgen;   Amgen;   Takeda Global Research & Development Center, Inc.
Recruiting - verified May 2012

Conditions:   Renal Cell Carcinoma;   Cancer
Interventions:   Drug: pazopanib;   Drug: placebo
Sponsors:   GlaxoSmithKline;   GlaxoSmithKline
Recruiting - verified May 2012

Condition:   Chronic Myelogenous Leukemia in Chronic Phase
Intervention:   Drug: nilotinib
Sponsors:   Novartis;   Novartis Pharmaceuticals
Recruiting - verified April 2012

Conditions:   Non-small Cell Lung Cancer;   Lung Cancer;   NSCLC
Intervention:   Radiation: Stereotactic radiotherapy
Sponsors:   Dana-Farber Cancer Institute;   Dana-Farber Cancer Institute;   Brigham and Women's Hospital
Recruiting - verified October 2011

Conditions:   Prostate Neoplasms;   Genital Neoplasms, Male;   Urogenital Neoplasms;   Genital Diseases, Male
Intervention:   Drug: Abiraterone Acetate
Sponsors:   Johnson & Johnson Pharmaceutical Research & Development, L.L.C.;   Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Available - verified April 2012

Conditions:   Neoplasms, Breast;   WT1-positive Primary Invasive Breast Cancer
Interventions:   Biological: GSK Biologicals' recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI) GSK2302024A;   Biological: Placebo
Sponsors:   GlaxoSmithKline;   GlaxoSmithKline
Recruiting - verified May 2012

Condition:   Acute Myeloid Leukemia (AML)
Intervention:   Drug: Panobinostat
Sponsors:   Novartis;   Novartis Pharmaceuticals
Recruiting - verified May 2012

Condition:   Brain and Central Nervous System Tumors
Interventions:   Biological: bevacizumab;   Drug: irinotecan hydrochloride;   Drug: temozolomide
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Sarcoma
Interventions:   Biological: bevacizumab;   Drug: cyclophosphamide;   Drug: temsirolimus;   Drug: vinorelbine tartrate
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Conditions:   Advanced Solid Tumors;   With an Alteration of the PIK3CA Gene
Intervention:   Drug: BYL719
Sponsors:   Novartis;   Novartis Pharmaceuticals
Recruiting - verified May 2012

Condition:   Breast Cancer
Interventions:   Drug: Sorafenib(Nexavar, BAY43-9006) / Capecitabine;   Drug: Placebo / Capecitabine
Sponsors:   Bayer;   Bayer;   Onyx Therapeutics, Inc.
Recruiting - verified April 2012

Conditions:   Patients With Multiple Myeloma Experiencing a;   First or Second Relapse
Intervention:   Drug: IPH2101 combined to lenalidomide
Sponsors:   Innate Pharma;   Innate Pharma
Recruiting - verified October 2011

Condition:   Prostate Cancer
Intervention:  
Sponsors:   Massachusetts General Hospital;   Massachusetts General Hospital
Recruiting - verified January 2012

Condition:   Adenocarcinoma of the Lung
Interventions:   Biological: farletuzumab;   Other: Placebo;   Drug: Platinum Containing Doublet
Sponsors:   Morphotek;   Morphotek
Recruiting - verified May 2012

Condition:   Prostate Cancer
Interventions:   Drug: MDV3100;   Drug: Placebo
Sponsors:   Medivation, Inc.;   Medivation, Inc.;   Astellas Pharma Inc
Recruiting - verified February 2012

Condition:   Lymphoma
Interventions:   Biological: rituximab;   Drug: bendamustine hydrochloride;   Drug: bortezomib;   Drug: lenalidomide
Sponsors:   National Cancer Institute (NCI);   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Endometrial Cancer
Intervention:   Biological: trebananib
Sponsors:   National Cancer Institute (NCI);   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Conditions:   Anal Cancer;   Nonneoplastic Condition;   Penile Cancer;   Precancerous Condition
Interventions:   Biological: quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine;   Other: laboratory biomarker analysis
Sponsors:   National Cancer Institute (NCI);   AIDS Associated Malignancies Clinical Trials Consortium;   National Cancer Institute (NCI)
Recruiting - verified February 2012

Conditions:   Pigmented Villonodular Synovitis;   Diffuse-type Giant Cell Tumor;   Tenosynovial Giant Cell Tumor
Intervention:   Drug: nilotinib
Sponsors:   Dana-Farber Cancer Institute;   Dana-Farber Cancer Institute;   Brigham and Women's Hospital;   Massachusetts General Hospital;   Novartis
Recruiting - verified June 2011

Condition:   Multiple Myeloma
Interventions:   Drug: Lenalidomide;   Drug: Bortezomib;   Drug: Dexamethasone;   Procedure: Autologous Stem Cell Transplant
Sponsors:   Dana-Farber Cancer Institute;   Dana-Farber Cancer Institute;   Celgene Corporation;   Millennium Pharmaceuticals, Inc.;   Massachusetts General Hospital;   Beth Israel Deaconess Medical Center;   Emory University;   University of Michigan;   Fox Chase Cancer Center;   Memorial Sloan-Kettering Cancer Center;   Fred Hutchinson Cancer Research Center;   Barbara Ann Karmanos Cancer Institute;   Duke University;   University of California, San Francisco;   University of Chicago;   M.D. Anderson Cancer Center;   UNC Lineberger Comprehensive Cancer Center
Recruiting - verified July 2011

Condition:   Multiple Myeloma
Intervention:   Drug: indium-111-ibritumomab tiuxetan
Sponsors:   Tufts Medical Center;   Tufts Medical Center;   Spectrum Pharmaceuticals, Inc
Recruiting - verified April 2012

Condition:   Neuroblastoma
Interventions:   Drug: isotretinoin;   Drug: vorinostat;   Other: laboratory biomarker analysis;   Other: pharmacological study
Sponsors:   National Cancer Institute (NCI);   New Approaches to Neuroblastoma Therapy Consortium;   National Cancer Institute (NCI)
Recruiting - verified August 2011

Conditions:   Bladder Neoplasm;   Intravesical Drug Administration;   Neoplasm Recurrence, Local;   Transitional Cell, Carcinoma;   Carcinoma in Situ;   Mycobacterium
Intervention:   Biological: EN3348
Sponsors:   Endo Pharmaceuticals;   Endo Pharmaceuticals
Recruiting - verified February 2012

Condition:   Kidney Cancer
Interventions:   Biological: bevacizumab;   Drug: everolimus;   Other: placebo
Sponsors:   National Cancer Institute (NCI);   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified February 2012

Conditions:   Adenocarcinoma of the Gastroesophageal Junction;   Esophageal Cancer
Interventions:   Biological: trastuzumab;   Drug: carboplatin;   Drug: paclitaxel
Sponsors:   National Cancer Institute (NCI);   Radiation Therapy Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Conditions:   Vestibular Schwannoma;   Acoustic Neuroma
Intervention:   Radiation: Fractionated proton radiation
Sponsors:   Massachusetts General Hospital;   Massachusetts General Hospital;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Prostate Cancer
Interventions:   Drug: Orteronel + prednisone;   Drug: Placebo + prednisone
Sponsors:   Millennium Pharmaceuticals, Inc.;   Millennium Pharmaceuticals, Inc.
Recruiting - verified February 2012

Conditions:   Esophageal Cancer;   Gastric Cancer
Interventions:   Drug: bevacizumab;   Drug: trastuzumab;   Drug: oxaliplatin;   Drug: capecitabine
Sponsors:   Dana-Farber Cancer Institute;   Dana-Farber Cancer Institute;   Brigham and Women's Hospital;   Massachusetts General Hospital;   Genentech
Recruiting - verified September 2011

Conditions:   Fallopian Tube Cancer;   Ovarian Cancer;   Primary Peritoneal Cancer
Interventions:   Drug: AMG 386;   Drug: AMG 386 Placebo
Sponsors:   Amgen;   Amgen
Recruiting - verified May 2012

Conditions:   Ovarian Cancer;   Fallopian Tube Cancer;   Peritoneal Cancer
Interventions:   Drug: carboplatin;   Drug: pralatrexate
Sponsors:   Massachusetts General Hospital;   Massachusetts General Hospital;   Dana-Farber Cancer Institute;   Brigham and Women's Hospital;   National Comprehensive Cancer Network
Recruiting - verified April 2012

Conditions:   Lymphoma;   Nonneoplastic Condition
Interventions:   Biological: rituximab;   Drug: EPOCH regimen;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: prednisone;   Drug: vincristine sulfate;   Drug: vorinostat;   Other: R-CHOP regimen
Sponsors:   National Cancer Institute (NCI);   AIDS Associated Malignancies Clinical Trials Consortium;   National Cancer Institute (NCI)
Recruiting - verified August 2011

Conditions:   Solid Tumor;   Kidney Cancer
Interventions:   Drug: pazopanib;   Drug: everolimus
Sponsors:   Dana-Farber Cancer Institute;   Dana-Farber Cancer Institute;   Beth Israel Deaconess Medical Center;   Brigham and Women's Hospital;   GlaxoSmithKline;   Novartis
Recruiting - verified February 2012

Condition:   Leukemia
Interventions:   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: dexamethasone;   Drug: doxorubicin hydrochloride;   Drug: leucovorin calcium;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: pegaspargase;   Drug: thioguanine;   Drug: vincristine sulfate
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Conditions:   Multiple Myeloma;   Relapsed Multiple Myeloma;   Refractory Multiple Myeloma
Intervention:   Drug: AT7519M, Bortezomib
Sponsors:   Astex Pharmaceuticals;   Astex Pharmaceuticals;   Multiple Myeloma Research Consortium
Recruiting - verified July 2011

Condition:   Breast Cancer
Interventions:   Drug: bevacizumab;   Drug: MetMAb;   Drug: paclitaxel;   Drug: placebo
Sponsors:   Genentech;   Genentech;   Hoffmann-La Roche
Recruiting - verified March 2012

Conditions:   Biliary Tract Cancer;   Gallbladder Cancer
Interventions:   Drug: Panitumumab;   Drug: oxaliplatin;   Drug: gemcitabine
Sponsors:   University of Rochester;   University of Rochester;   Amgen
Recruiting - verified November 2011

Condition:   Diffuse Intrinsic Pontine Glioma
Interventions:   Drug: Bevacizumab;   Drug: Erlotinib;   Drug: Temozolomide;   Radiation: Irradiation
Sponsors:   Dana-Farber Cancer Institute;   Dana-Farber Cancer Institute;   University of California, San Francisco;   Children's Hospital Boston;   Children's Memorial Hospital;   Children's Hospital Los Angeles;   University of Utah;   Memorial Sloan-Kettering Cancer Center;   Seattle Children's Hospital;   Children's Hospital Colorad;   Doernbecher Children's Hospital;   Washington University Children's Hospital;   Miami Children's Hospital;   Johns Hopkins University;   University of Florida;   Children's Hospitals and Clinics of Minnesota;   Southwestern Regional Medical Center;   New York University;   University of Rochester;   University of Mississippi Medical Center;   Louisville Children's Hospital;   Children's Healthcare of Atlanta
Recruiting - verified September 2011

Conditions:   Diffuse, Large B-Cell, Lymphoma;   Lymphoma, Low-Grade;   T-Cell Lymphoma;   Mantle-Cell Lymphoma;   Hodgkin's Lymphoma;   Chronic Lymphocytic Leukemia;   Lymphoma, Small Lymphocytic
Interventions:   Drug: Busulfan;   Drug: Etoposide;   Drug: Cyclophosphamide;   Drug: Mesna;   Drug: Phenytoin;   Drug: Ursodiol;   Other: Infusion of autologous peripheral blood stem cells;   Drug: Neupogen;   Drug: Fludarabine;   Drug: Busulfan;   Other: Peripheral blood stem cell transplant;   Drug: Tacrolimus;   Drug: Sirolimus;   Drug: Methotrexate
Sponsors:   Massachusetts General Hospital;   Massachusetts General Hospital;   Dana-Farber Cancer Institute
Recruiting - verified April 2012

Conditions:   Multiple Myeloma;   Waldenstrom's Macroglobulinemia;   Smoldering Multiple Myeloma;   Lymphoblastic Lymphoma
Intervention:  
Sponsors:   Dana-Farber Cancer Institute;   Dana-Farber Cancer Institute;   Steven and Michele Kirsch Foundation for Waldenstrom's Macroglobulinemia
Recruiting - verified November 2011

Condition:   Small Cell Lung Cancer
Intervention:   Drug: STA-9090
Sponsors:   Dana-Farber Cancer Institute;   Leena Gandhi, MD, PhD;   Massachusetts General Hospital;   Beth Israel Deaconess Medical Center;   Synta Pharmaceuticals Corp.
Recruiting - verified July 2010

Conditions:   Estrogen Receptor Negative (ER-Negative) Breast Cancer;   Progesterone Receptor Negative (PR-Negative) Breast Cancer;   Human Epidermal Growth Factor Receptor 2 Negative (HER2-Negative) Breast Cancer;   Brain Metastases
Intervention:   Drug: INIPARIB + irinotecan
Sponsors:   Sanofi-Aventis;   Sanofi-Aventis;   UNC Lineberger Comprehensive Cancer Center
Recruiting - verified October 2011

Condition:   Cervical Cancer
Intervention:   Behavioral: BNI-brief Negotiated Interview
Sponsors:   Boston Medical Center;   Boston Medical Center
Recruiting - verified December 2010

Condition:   Prostate Cancer
Intervention:   Drug: ARN-509
Sponsors:   Aragon Pharmaceuticals, Inc.;   Aragon Pharmaceuticals, Inc.
Recruiting - verified March 2012

Condition:   Pediatric Acute Myelogenous Leukemia (AML)
Interventions:   Drug: Decitabine;   Drug: Decitabine
Sponsors:   Eisai Inc.;   Eisai Inc.
Recruiting - verified April 2012

Condition:   Chordoma
Intervention:   Drug: Imatinib + LBH589
Sponsors:   University of Virginia;   Deric M Park MD
Recruiting - verified February 2012

Conditions:   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma
Interventions:   Drug: dasatinib;   Drug: Rituximab;   Drug: fludarabine
Sponsors:   Massachusetts General Hospital;   Massachusetts General Hospital;   Dana-Farber Cancer Institute;   Bristol-Myers Squibb
Recruiting - verified April 2012

Condition:   Non Small Cell Lung Cancer
Interventions:   Drug: Docetaxel;   Biological: Ramucirumab;   Drug: Placebo
Sponsors:   Eli Lilly and Company;   Eli Lilly and Company;   ImClone LLC
Recruiting - verified May 2012

Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Neoplasms;   Unspecified Childhood Solid Tumor, Protocol Specific
Interventions:   Drug: ruxolitinib phosphate;   Other: laboratory biomarker analysis;   Other: pharmacological study
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2012

Condition:   Soft Tissue Sarcoma
Interventions:   Drug: doxorubicin in combination with palifosfamide-tris;   Drug: doxorubicin in combination with placebo
Sponsors:   ZIOPHARM;   ZIOPHARM
Recruiting - verified April 2012

Condition:   Carcinoma, Squamous Cell of the Head and Neck
Interventions:   Biological: REOLYSIN;   Drug: Carboplatin;   Drug: Paclitaxel;   Drug: Placebo
Sponsors:   Oncolytics Biotech;   Oncolytics Biotech
Recruiting - verified March 2012

Condition:   Ovarian Cancer
Interventions:   Drug: EC145;   Drug: Pegylated Liposomal Doxorubicin (PLD/Doxil®/Caelyx®);   Drug: placebo;   Drug: EC20
Sponsors:   Endocyte;   Endocyte
Recruiting - verified March 2012

Conditions:   Brain and Central Nervous System Tumors;   Childhood Germ Cell Tumor;   Kidney Cancer;   Leukemia;   Liver Cancer;   Neuroblastoma;   Sarcoma
Interventions:   Drug: alisertib;   Other: laboratory biomarker analysis;   Other: pharmacological study
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Bladder Cancer Requiring Cystectomy
Interventions:   Other: Quality of Life Questionnaires;   Other: Get up and Go test;   Other: Hand Grip test
Sponsors:   The University of Texas Health Science Center at San Antonio;   The University of Texas Health Science Center at San Antonio;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Non Squamous Lung Cancer
Interventions:   Drug: treatment;   Drug: treatment
Sponsors:   Pfizer;   Pfizer
Recruiting - verified April 2012

Condition:   Head and Neck Squamous Cell Carcinoma
Interventions:   Drug: Paclitaxel;   Drug: Carboplatin;   Drug: Cetuximab;   Drug: Cetuximab;   Drug: Docetaxel;   Drug: Cisplatin;   Drug: Fluorouracil;   Radiation: Radiotherapy (RT);   Other: Chemotherapy
Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center
Recruiting - verified May 2012

Conditions:   Minimal Residual Disease;   Leukemia, Lymphoblastic, Acute;   Leukemia, Myelogenous, Acute
Interventions:   Drug: Clofarabine;   Drug: Cytarabine;   Drug: Methotrexate;   Drug: Cytarabine
Sponsors:   Therapeutic Advances in Childhood Leukemia Consortium;   Therapeutic Advances in Childhood Leukemia Consortium;   Genzyme
Recruiting - verified November 2011

Condition:   Cancer
Intervention:  
Sponsors:   St. Jude Children's Research Hospital;   St. Jude Children's Research Hospital;   National Institutes of Health (NIH);   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified February 2012

Condition:   Her2 Negative Breast Cancer Patients
Interventions:   Drug: MM-121 (SAR256212) and Exemestane;   Drug: Placebo and Exemestane
Sponsors:   Merrimack Pharmaceuticals;   Merrimack Pharmaceuticals
Recruiting - verified May 2012

Condition:   Colorectal Cancer
Interventions:   Drug: celecoxib;   Drug: fluorouracil;   Drug: leucovorin calcium;   Drug: oxaliplatin;   Other: placebo
Sponsors:   National Cancer Institute (NCI);   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified February 2012

Condition:   Glioma
Intervention:   Drug: RAD001 (Everolimus)
Sponsors:   University of Alabama at Birmingham;   University of Alabama at Birmingham;   Children's Hospital Boston;   Children's Hospital of Philadelphia;   Children's Research Institute;   Children's Hospital Medical Center, Cincinnati;   National Cancer Institute (NCI);   University of Chicago;   University of Utah;   Washington University School of Medicine
Recruiting - verified May 2012

Condition:   Rectal Cancer
Intervention:   Radiation: Intensity Modulated Radiation Therapy
Sponsors:   Massachusetts General Hospital;   Massachusetts General Hospital;   Dana-Farber Cancer Institute;   Brigham and Women's Hospital;   National Institutes of Health (NIH)
Recruiting - verified December 2011

Condition:   Prostate Cancer
Interventions:   Biological: fowlpox-PSA-TRICOM vaccine;   Biological: vaccinia-PSA-TRICOM vaccine;   Drug: docetaxel;   Drug: prednisone
Sponsors:   National Cancer Institute (NCI);   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified September 2011

Conditions:   Solid Tumor;   Liver Metastases
Interventions:   Radiation: stereotactic body radiotherapy-photon;   Radiation: Stereotactic body radiotherapy-proton
Sponsors:   Massachusetts General Hospital;   Massachusetts General Hospital;   Dana-Farber Cancer Institute;   Brigham and Women's Hospital;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Conditions:   Breast Cancer;   Fallopian Tube Cancer;   Ovarian Cancer;   Primary Peritoneal Cavity Cancer
Interventions:   Other: questionnaire administration;   Procedure: evaluation of cancer risk factors;   Procedure: quality-of-life assessment;   Procedure: study of high risk factors
Sponsors:   National Cancer Institute (NCI);   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Leukemia
Interventions:   Genetic: DNA ploidy analysis;   Genetic: chromosomal translocation analysis;   Genetic: cytogenetic analysis;   Genetic: fluorescence in situ hybridization;   Other: cytology specimen collection procedure;   Other: flow cytometry;   Other: laboratory biomarker analysis
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Sarcoma
Interventions:   Biological: Trivalent ganglioside vaccine;   Biological: OPT-821
Sponsors:   MabVax Therapeutics, Inc.;   MabVax Therapeutics, Inc.
Recruiting - verified March 2012

Condition:   Neoplasm Malignant
Intervention:   Drug: Cabazitaxel (XRP6258)
Sponsors:   Sanofi-Aventis;   Sanofi-Aventis
Recruiting - verified May 2012

Condition:   Hepatocellular Carcinoma
Interventions:   Biological: Placebo;   Biological: Ramucirumab DP (IMC-1121B)
Sponsors:   ImClone LLC;   ImClone LLC
Recruiting - verified February 2012

Condition:   Glioma
Interventions:   Drug: E7080;   Drug: E7080;   Drug: E7080
Sponsors:   Eisai Inc.;   Eisai Inc.
Recruiting - verified April 2012

Condition:   Unresectable Stage III or Stage IV Melanoma
Interventions:   Drug: E7080;   Drug: E7080
Sponsors:   Eisai Inc.;   Eisai Inc.
Recruiting - verified January 2012

Condition:   Leukemia
Intervention:  
Sponsors:   University of Massachusetts, Worcester;   University of Massachusetts, Worcester
Recruiting - verified February 2012

Condition:   Metastatic Renal Cell Carcinoma
Interventions:   Drug: E7080;   Drug: Everolimus;   Drug: E7080 plus Everolimus
Sponsors:   Eisai Inc.;   Eisai Inc.
Recruiting - verified April 2012

Condition:   Lymphoma
Interventions:   Biological: bleomycin sulfate;   Drug: ABVD regimen;   Drug: BEACOPP regimen;   Drug: cyclophosphamide;   Drug: dacarbazine;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: prednisone;   Drug: procarbazine hydrochloride;   Drug: vinblastine sulfate;   Drug: vincristine sulfate;   Other: laboratory biomarker analysis;   Procedure: computed tomography;   Radiation: fludeoxyglucose F 18;   Radiation: radiation therapy
Sponsors:   National Cancer Institute (NCI);   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Chronic Myelogenous Leukemia
Intervention:   Drug: Zileuton
Sponsors:   University of Massachusetts, Worcester;   University of Massachusetts, Worcester
Recruiting - verified February 2012

Condition:   Breast Cancer
Interventions:   Drug: tamoxifen citrate;   Other: laboratory biomarker analysis
Sponsors:   National Cancer Institute (NCI);   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified February 2012

Condition:   Non-small-cell Lung Cancer
Intervention:   Drug: AUY922
Sponsors:   Novartis;   Novartis Pharmaceuticals
Recruiting - verified April 2012

Condition:   Barrett's Esophagus, Esophageal Intraepithelial Neoplasia
Intervention:   Procedure: endomicroscopy
Sponsors:   Johns Hopkins University;   Johns Hopkins University;   American Society for Gastrointestinal Endoscopy;   Pentax Medical Corporation
Recruiting - verified March 2012

Condition:   Non Small Cell Lung Cancer
Interventions:   Drug: COMBINED PF-02341066 AND PF-00299804;   Drug: PF-00299804 FOLLOWED BY COMBINED PF-02341066 AND PF-00299804
Sponsors:   Pfizer;   Pfizer
Recruiting - verified May 2012

Condition:   Neoplasms Malignant
Intervention:   Drug: Crizotinib
Sponsors:   Pfizer;   Pfizer
Recruiting - verified April 2012

Condition:   Kidney Cancer
Interventions:   Drug: everolimus;   Other: placebo
Sponsors:   National Cancer Institute (NCI);   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified February 2012

Conditions:   Medulloblastoma,;   Rhabdomyosarcoma,;   Neuroblastoma,;   Hepatoblastoma,;   High Grade Glioma,;   Astrocytoma
Intervention:   Drug: LDE225
Sponsors:   Novartis;   Novartis Pharmaceuticals
Recruiting - verified April 2012

Condition:   Cancer
Intervention:  
Sponsors:   St. Jude Children's Research Hospital;   St. Jude Children's Research Hospital;   National Cancer Institute (NCI);   Fred Hutchinson Cancer Research Center;   Nationwide Children's Hospital;   M.D. Anderson Cancer Center;   University of Southern California;   Children's Hospital Medical Center, Cincinnati
Recruiting - verified April 2012

Conditions:   Fallopian Tube Cancer;   Ovarian Cancer;   Primary Peritoneal Cavity Cancer
Interventions:   Biological: EGEN-001;   Other: laboratory biomarker analysis
Sponsors:   National Cancer Institute (NCI);   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2012

Conditions:   Acute Myelogenous Leukemia;   Diffuse Large B-Cell Leukemia;   Chronic Lymphocytic Leukemia;   Follicular Lymphoma
Interventions:   Drug: BMS-936564 (Anti-CXCR4);   Drug: BMS-936564 (Anti-CXCR4)
Sponsors:   Bristol-Myers Squibb;   Bristol-Myers Squibb
Recruiting - verified December 2011

Conditions:   Brain Tumors;   Non-CNS Malignancies
Intervention:   Other: Quality of Life surveys completed at specified timepoints
Sponsors:   Massachusetts General Hospital;   Massachusetts General Hospital;   M.D. Anderson Cancer Center
Recruiting - verified April 2012

Conditions:   Ovarian Cancer;   Primary Peritoneal Cancer;   Fallopian Tube Cancer
Interventions:   Drug: cediranib;   Drug: olaparib
Sponsors:   Dana-Farber Cancer Institute;   Dana-Farber Cancer Institute;   Massachusetts General Hospital;   Beth Israel Deaconess Medical Center;   University of Chicago;   National Cancer Institute (NCI)
Recruiting - verified April 2012

Conditions:   Relapsed or Refractory Multiple Myeloma;   Waldenstrom Macroglobulinemia
Intervention:   Drug: INK128
Sponsors:   Intellikine;   Intellikine
Recruiting - verified January 2012

Conditions:   Breast Cancer;   Fatigue
Intervention:  
Sponsors:   Massachusetts General Hospital;   Massachusetts General Hospital
Recruiting - verified April 2012

Condition:   Breast Cancer
Interventions:   Drug: trastuzumab emtansine;   Drug: pertuzumab;   Drug: pertuzumab-placebo;   Drug: trastuzumab [Herceptin];   Drug: docetaxel;   Drug: paclitaxel
Sponsors:   Hoffmann-La Roche;   Hoffmann-La Roche;   Genentech
Recruiting - verified March 2012

Conditions:   Renal Cell Carcinoma;   Pharmacokinetics of AGS-16M8F
Intervention:   Drug: AGS-16M8F
Sponsors:   Astellas Pharma Inc;   Astellas Pharma Inc;   Agensys, Inc.
Recruiting - verified March 2012

Condition:   Lymphoma
Interventions:   Biological: bleomycin sulfate;   Drug: ABVD regimen;   Drug: BEACOPP regimen;   Drug: cyclophosphamide;   Drug: dacarbazine;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: prednisone;   Drug: procarbazine hydrochloride;   Drug: vinblastine sulfate;   Drug: vincristine sulfate;   Other: laboratory biomarker analysis;   Procedure: computed tomography;   Radiation: fludeoxyglucose F 18;   Radiation: radiation therapy
Sponsors:   National Cancer Institute (NCI);   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified April 2012

Condition:   Lung Cancer
Interventions:   Biological: bevacizumab;   Drug: pemetrexed disodium
Sponsors:   National Cancer Institute (NCI);   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified February 2012

Conditions:   Non-Hodgkin's Lymphoma;   CNS Lymphoma
Intervention:   Procedure: High-dose chemotherapy with autologous stem cell transplant
Sponsors:   Massachusetts General Hospital;   Massachusetts General Hospital;   Genentech;   Otsuka America Pharmaceutical;   Dana-Farber Cancer Institute
Recruiting - verified April 2012

Conditions:   Glioblastoma;   GBM;   Glioblastoma Multiforme
Intervention:   Drug: PF-00299804
Sponsors:   Massachusetts General Hospital;   Massachusetts General Hospital;   Dana-Farber Cancer Institute;   Brigham and Women's Hospital;   Henry Ford Hospital;   Pfizer
Recruiting - verified April 2012

Conditions:   Bone Metastases;   Castration-Resistant Prostate Cancer
Interventions:   Drug: Alpharadin® (Radium-223 chloride) + docetaxel;   Drug: Docetaxel
Sponsors:   Algeta ASA;   Algeta ASA;   Bayer
Recruiting - verified October 2011

Condition:   Endometrial Cancer
Intervention:   Drug: E7080
Sponsors:   Eisai Inc.;   Eisai Inc.
Recruiting - verified April 2012

Condition:   Multiple Myeloma
Interventions:   Drug: Lenalidomide;   Drug: lenalidomide, bortezomib and dexamethasone;   Drug: Lenalidomide
Sponsors:   National Heart, Lung, and Blood Institute (NHLBI);   National Heart, Lung, and Blood Institute (NHLBI);   Blood and Marrow Transplant Clinical Trials Network;   National Cancer Institute (NCI)
Recruiting - verified March 2012

Condition:   Peripheral T-cell Lymphoma
Intervention:  
Sponsors:   Allos Therapeutics;   Allos Therapeutics
Recruiting - verified December 2011

Condition:   Breast Cancer
Interventions:   Drug: metformin hydrochloride;   Other: placebo
Sponsors:   NCIC Clinical Trials Group;   NCIC Clinical Trials Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Conditions:   Chemotherapeutic Agent Toxicity;   Colorectal Cancer;   Neuropathy;   Neurotoxicity
Interventions:   Drug: calcium gluconate;   Drug: magnesium sulfate;   Other: placebo
Sponsors:   National Cancer Institute (NCI);   North Central Cancer Treatment Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Conditions:   brca1 Mutation Carrier;   brca2 Mutation Carrier;   Breast Cancer
Interventions:   Dietary Supplement: cholecalciferol;   Other: placebo
Sponsors:   National Cancer Institute (NCI);   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Conditions:   HER2 Amplified Breast Cancer;   Metastatic or Advanced Breast Cancer
Intervention:   Drug: MM-111 and Herceptin
Sponsors:   Merrimack Pharmaceuticals;   Merrimack Pharmaceuticals
Recruiting - verified March 2012

Condition:   Brain and Central Nervous System Tumors
Interventions:   Drug: cisplatin;   Drug: cyclophosphamide;   Drug: etoposide;   Drug: vincristine sulfate;   Other: clinical observation;   Radiation: 3-dimensional conformal radiation therapy
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Disease, Hodgkin
Interventions:   Drug: brentuximab vedotin;   Drug: placebo
Sponsors:   Seattle Genetics, Inc.;   Seattle Genetics, Inc.;   Millennium Pharmaceuticals, Inc.
Recruiting - verified April 2012

Conditions:   Acute Myelogenous Leukemia;   AML
Interventions:   Biological: DC AML Vaccine;   Drug: CT-011
Sponsors:   Dana-Farber Cancer Institute;   Beth Israel Deaconess Medical Center;   National Institutes of Health (NIH);   CureTech Ltd
Recruiting - verified November 2011

Conditions:   Thymoma;   Thymic Carcinoma
Interventions:   Drug: Belinostat;   Drug: Cisplatin;   Drug: Cyclophosphamide;   Drug: Doxorubicin
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified November 2011

Conditions:   Burkitt Lymphoma;   Diffuse Large B-cell Lymphoma, c-MYC Positive
Interventions:   Drug: rituximab;   Drug: etoposide;   Drug: cyclophosphamide;   Drug: doxorubicin;   Drug: vincristine;   Drug: prednisone;   Drug: filgrastim
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified September 2011

Conditions:   Chronic Lymphocytic Leukemia;   Lymphoma, Non-Hodgkin;   Acute Myeloid Leukemia;   Multiple Myeloma
Intervention:   Drug: CAL-101
Sponsors:   Gilead Sciences;   Gilead Sciences
Recruiting - verified January 2012

Conditions:   Head and Neck Cancer;   Precancerous Condition
Interventions:   Biological: cetuximab;   Radiation: intensity-modulated radiation therapy
Sponsors:   National Cancer Institute (NCI);   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified June 2011

Condition:   Carcinoma, Non-Small-Cell Lung
Intervention:   Drug: BIBW 2992 plus cetuximab
Sponsors:   Boehringer Ingelheim Pharmaceuticals;   Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012

Condition:   Waldenstrom's Macroglobulinemia
Interventions:   Drug: Everolimus;   Drug: Rituximab;   Drug: Bortezomib
Sponsors:   Dana-Farber Cancer Institute;   Dana-Farber Cancer Institute;   Novartis;   Millennium Pharmaceuticals, Inc.
Recruiting - verified May 2012

Condition:   Liver Cancer
Interventions:   Drug: iodinated contrast dye;   Drug: motexafin gadolinium;   Other: laboratory biomarker analysis
Sponsors:   National Cancer Institute (NCI);   American College of Radiology Imaging Network;   National Cancer Institute (NCI)
Recruiting - verified January 2012

Condition:   Breast Cancer
Interventions:   Other: circulating tumor cell analysis;   Other: laboratory biomarker analysis;   Other: questionnaire administration;   Procedure: adjuvant therapy;   Radiation: 3-dimensional conformal accelerated partial breast irradiation
Sponsors:   National Cancer Institute (NCI);   Radiation Therapy Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified July 2011

Conditions:   Fallopian Tube Cancer;   Ovarian Cancer
Interventions:   Biological: bevacizumab;   Drug: capecitabine;   Drug: carboplatin;   Drug: oxaliplatin;   Drug: paclitaxel;   Procedure: quality-of-life assessment
Sponsors:   University College, London;   University College, London;   National Cancer Institute (NCI);   Gynecologic Oncology Group
Recruiting - verified December 2011

Condition:   Breast Cancer
Interventions:   Drug: XL147 (SAR245408);   Drug: XL765 (SAR245409);   Drug: letrozole (Femara)
Sponsors:   Sanofi-Aventis;   Sanofi-Aventis
Recruiting - verified April 2012

Conditions:   Cognitive/Functional Effects;   Fallopian Tube Cancer;   Ovarian Cancer;   Primary Peritoneal Cavity Cancer
Interventions:   Drug: systemic chemotherapy;   Other: questionnaire administration;   Procedure: assessment of therapy complications;   Procedure: cognitive assessment;   Procedure: quality-of-life assessment
Sponsors:   National Cancer Institute (NCI);   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified October 2011

Condition:   Head and Neck Cancer
Interventions:   Drug: cetuximab;   Drug: Cisplatin;   Drug: Carboplatin;   Drug: 5-fluorouracil
Sponsors:   Eli Lilly and Company;   Eli Lilly and Company
Recruiting - verified May 2012

Condition:   Colorectal Cancer
Interventions:   Biological: cetuximab;   Biological: ramucirumab;   Drug: irinotecan hydrochloride
Sponsors:   National Cancer Institute (NCI);   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified April 2012

Condition:   Multiple Myeloma
Intervention:  
Sponsors:   Celgene Corporation;   Celgene Corporation
Recruiting - verified June 2011

Condition:   Chronic Lymphocytic Leukemia
Intervention:  
Sponsors:   Celgene Corporation;   Celgene Corporation
Recruiting - verified March 2011

Conditions:   Non-small Cell Lung Cancer;   EGFR Mutations
Intervention:   Drug: BIBW 2992
Sponsors:   Massachusetts General Hospital;   Massachusetts General Hospital;   Dana-Farber Cancer Institute;   Beth Israel Deaconess Medical Center;   Boehringer Ingelheim Pharmaceuticals
Recruiting - verified December 2011

Condition:   Melanoma
Interventions:   Drug: bortezomib;   Drug: sorafenib
Sponsors:   Dana-Farber Cancer Institute;   Massachusetts General Hospital;   Dana-Farber Cancer Institute;   Beth Isreal Deaconess Medical Center;   Brigham and Women's Hospital;   Bayer;   Millennium Pharmaceuticals, Inc.
Recruiting - verified October 2011

Condition:   Waldenstrom's Macroglobulinemia
Interventions:   Drug: pomalidomide;   Drug: dexamethasone;   Drug: rituximab
Sponsors:   Dana-Farber Cancer Institute;   Dana-Farber Cancer Institute;   Celgene Corporation
Recruiting - verified June 2011

Condition:   Pancreatic Cancer
Interventions:   Biological: HyperAcute-Pancreas Immunotherapy;   Drug: Gemcitabine;   Radiation: 5FU Chemoradiation
Sponsors:   NewLink Genetics Corporation;   NewLink Genetics Corporation
Recruiting - verified May 2012

Condition:   Polycystic Ovary Syndrome
Intervention:   Behavioral: Nutrition Education, Dietary Counseling, and Cooking
Sponsors:   Children's Hospital Boston;   Children's Hospital Boston;   Thrasher Research Fund
Recruiting - verified June 2011

Condition:   Cancer
Interventions:   Drug: GSK2118436;   Drug: GSK1120212
Sponsors:   GlaxoSmithKline;   GlaxoSmithKline
Recruiting - verified December 2011

Condition:   Acute Myeloid Leukemia
Interventions:   Drug: A: Azacitidine (Vidaza);   Drug: B: Conventional Care Regimen
Sponsors:   Celgene Corporation;   Celgene Corporation
Recruiting - verified March 2012

Condition:   Breast Cancer
Interventions:   Drug: Placebo;   Drug: Denosumab
Sponsors:   Amgen;   Amgen;   Daiichi Sankyo Inc.
Recruiting - verified May 2012

Conditions:   Cancer;   Metastatic Cancer;   Incurable Cancer Diseases
Intervention:  
Sponsors:   Massachusetts General Hospital;   Massachusetts General Hospital
Recruiting - verified March 2012

Conditions:   Brain Tumor;   Medulloblastoma;   Pineoblastoma
Intervention:   Radiation: proton beam radiation
Sponsors:   Massachusetts General Hospital;   Massachusetts General Hospital;   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
Recruiting - verified September 2011

Conditions:   Melanoma;   Malignant Melanoma
Intervention:   Drug: LBH589
Sponsors:   Dana-Farber Cancer Institute;   Dana-Farber Cancer Institute;   Brigham and Women's Hospital;   Novartis
Recruiting - verified October 2011

Conditions:   Chronic Lymphocytic Leukemia;   Small Lymphocytic Leukemia
Intervention:   Drug: pyrimethamine
Sponsors:   Dana-Farber Cancer Institute;   Dana-Farber Cancer Institute;   Brigham and Women's Hospital;   Beth Israel Deaconess Medical Center;   Lymphoma Research Foundation
Recruiting - verified February 2012

Condition:   Advanced Solid Malignancies
Intervention:   Drug: INK128
Sponsors:   Intellikine;   Intellikine
Recruiting - verified January 2012

Condition:   Lung Cancer
Interventions:   Radiation: prophylactic cranial irradiation;   Radiation: selective external radiation therapy
Sponsors:   National Cancer Institute (NCI);   Radiation Therapy Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified April 2012

Conditions:   Post-transplant Lymphoproliferative Disease;   Solid Organ Transplant;   Stem Cell Transplant (Bone Marrow Transplant);   Epstein Barr Virus Infections
Interventions:   Drug: bortezomib;   Drug: rituximab
Sponsors:   Massachusetts General Hospital;   Massachusetts General Hospital;   Dana-Farber Cancer Institute;   Brigham and Women's Hospital;   Beth Israel Deaconess Medical Center;   Millennium Pharmaceuticals, Inc.
Recruiting - verified February 2012

Condition:   Sarcoma
Interventions:   Biological: cixutumumab;   Biological: dactinomycin;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: ifosfamide;   Drug: irinotecan hydrochloride;   Drug: temozolomide;   Drug: vincristine sulfate
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Conditions:   Liver Metastases;   Primary Liver Cancers
Intervention:   Biological: administration of rRp450 into the hepatic artery
Sponsors:   Massachusetts General Hospital;   Kenneth K. Tanabe, MD;   National Cancer Institute (NCI)
Recruiting - verified April 2012

Conditions:   Cancer;   Cardiovascular Disease
Interventions:   Dietary Supplement: vitamin D3;   Dietary Supplement: omega-3 fatty acids (fish oil);   Dietary Supplement: Vitamin D3 placebo;   Dietary Supplement: Fish oil placebo
Sponsors:   Brigham and Women's Hospital;   Brigham and Women's Hospital;   National Cancer Institute (NCI);   National Heart, Lung, and Blood Institute (NHLBI);   Office of Dietary Supplements (ODS);   National Institute of Neurological Disorders and Stroke (NINDS);   National Center for Complementary and Alternative Medicine (NCCAM)
Recruiting - verified May 2012

Condition:   Lung Cancer
Interventions:   Drug: carboplatin;   Drug: celecoxib;   Drug: gemcitabine hydrochloride;   Drug: pemetrexed disodium;   Other: placebo
Sponsors:   National Cancer Institute (NCI);   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified February 2012

Condition:   Neuroblastoma
Interventions:   Biological: aldesleukin;   Biological: monoclonal antibody Ch14.18;   Biological: sargramostim;   Drug: isotretinoin;   Other: laboratory biomarker analysis
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified April 2011

Condition:   Leukemia
Interventions:   Drug: clofarabine;   Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: decitabine;   Other: clinical observation
Sponsors:   National Cancer Institute (NCI);   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified January 2012

Condition:   Ovarian Cancer
Intervention:   Drug: BSI-201
Sponsors:   Sanofi-Aventis;   Sanofi-Aventis;   BiPar Sciences
Recruiting - verified June 2011

Condition:   Refractory Multiple Myeloma
Interventions:   Drug: Aurora A kinase inhibitor MLN8237;   Drug: bortezomib
Sponsors:   Mayo Clinic;   Mayo Clinic
Recruiting - verified March 2012

Condition:   Carcinoma
Intervention:   Drug: Everolimus
Sponsors:   Novartis;   Novartis Pharmaceuticals
Recruiting - verified March 2012

Conditions:   WT1-positive Acute Myeloid Leukemia;   Leukaemia, Myelocytic, Acute
Intervention:   Biological: GSK Biologicals' recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI) GSK2130579A
Sponsors:   GlaxoSmithKline;   GlaxoSmithKline
Recruiting - verified March 2012

Condition:   Recurrent or Refractory Pediatric Ependymoma
Interventions:   Drug: erlotinib;   Drug: etoposide
Sponsors:   OSI Pharmaceuticals;   OSI Pharmaceuticals;   Astellas Pharma Global Development, Inc.
Recruiting - verified February 2012

Condition:   Sarcoma
Interventions:   Drug: PCI-24781;   Drug: Doxorubicin
Sponsors:   Massachusetts General Hospital;   Massachusetts General Hospital;   Dana-Farber Cancer Institute;   Brigham and Women's Hospital;   Pharmacyclics
Recruiting - verified April 2012

Condition:   Melanoma
Intervention:   Drug: nilotinib (AMN107)
Sponsors:   Novartis;   Novartis Pharmaceuticals
Recruiting - verified May 2012

Condition:   Multiple Myeloma
Interventions:   Drug: Panobinostat;   Drug: Bortezomib
Sponsors:   Novartis;   Novartis Pharmaceuticals
Recruiting - verified April 2012

Conditions:   Leukemia;   Lymphoma
Interventions:   Biological: anti-thymocyte globulin;   Biological: rituximab;   Drug: busulfan;   Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Drug: methotrexate;   Drug: sirolimus;   Drug: tacrolimus;   Other: laboratory biomarker analysis;   Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation
Sponsors:   National Cancer Institute (NCI);   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Liver Cancer
Interventions:   Drug: doxorubicin hydrochloride;   Drug: sorafenib tosylate
Sponsors:   National Cancer Institute (NCI);   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified September 2011

Condition:   Neuroblastoma
Interventions:   Drug: Vorinostat;   Radiation: 131- I Metaiodobenzylguanidine;   Procedure: Peripheral Blood Stem Cell Infusion;   Drug: Filgrastim
Sponsors:   New Approaches to Neuroblastoma Therapy Consortium;   New Approaches to Neuroblastoma Therapy Consortium;   National Cancer Institute (NCI)
Recruiting - verified April 2012

Conditions:   Brain Cancer;   Choroid Plexus Tumors
Interventions:   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Cyclophosphamide;   Drug: Dactinomycin;   Drug: Doxorubicin;   Drug: Etoposide;   Drug: Irinotecan;   Drug: Leucovorin;   Drug: Methotrexate;   Drug: Temozolomide;   Drug: Vincristine
Sponsors:   Tufts Medical Center;   Tufts Medical Center
Recruiting - verified April 2012

Condition:   Pancreatic Cancer
Interventions:   Drug: capecitabine;   Drug: erlotinib hydrochloride;   Drug: fluorouracil;   Drug: gemcitabine hydrochloride;   Radiation: 3-dimensional conformal radiation therapy;   Radiation: intensity-modulated radiation therapy
Sponsors:   National Cancer Institute (NCI);   Radiation Therapy Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Brain Cancer
Intervention:   Other: cetuximab in conjunction with external beam radiation therapy, followed by cetuximab and irinotecan
Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center;   Children's Healthcare of Atlanta;   Dana-Farber Cancer Institute;   M.D. Anderson Cancer Center;   Phoenix Children's Hospital;   Alberta Children's Hospital;   University of Colorado, Denver;   Seattle Children's Hospital;   Johns Hopkins University;   Children's Mercy Hospital-Kansas City, MO;   MD Anderson Cancer Center Orlando at Arnold Palmer Hospital for Children
Recruiting - verified March 2012

Condition:   Ileal Pouch-Anal Anastomosis
Intervention:  
Sponsors:   Boston Medical Center;   Boston Medical Center
Recruiting - verified June 2011

Conditions:   Colorectal Cancer;   Precancerous Condition
Interventions:   Drug: rosuvastatin;   Other: placebo
Sponsors:   National Cancer Institute (NCI);   National Surgical Adjuvant Breast and Bowel Project (NSABP);   National Cancer Institute (NCI)
Recruiting - verified February 2012

Conditions:   Endometrial Cancer;   Endometrial Neoplasms
Intervention:   Drug: XL147 (SAR245408)
Sponsors:   Sanofi-Aventis;   Sanofi-Aventis
Recruiting - verified April 2012

Condition:   Advanced Solid Tumors
Intervention:   Drug: XMT-1107
Sponsors:   Mersana Therapeutics;   Mersana Therapeutics
Recruiting - verified September 2011

Condition:   Sarcoma
Interventions:   Drug: bortezomib;   Genetic: RNA analysis;   Genetic: gene expression analysis;   Genetic: reverse transcriptase-polymerase chain reaction;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis
Sponsors:   AIDS Malignancy Clinical Trials Consortium;   AIDS Malignancy Clinical Trials Consortium;   National Cancer Institute (NCI)
Recruiting - verified November 2011

Conditions:   Breast Cancer;   Cardiac Toxicity
Interventions:   Drug: carvedilol phosphate extended-release capsule;   Drug: lisinopril;   Other: placebo
Sponsors:   National Cancer Institute (NCI);   University of South Florida;   National Cancer Institute (NCI)
Recruiting - verified February 2012

Condition:   Sarcoma
Interventions:   Biological: bevacizumab;   Biological: filgrastim;   Biological: pegfilgrastim;   Drug: docetaxel;   Drug: gemcitabine hydrochloride;   Other: placebo
Sponsors:   National Cancer Institute (NCI);   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Conditions:   HER2/Neu Over-expressing Locally Advanced Breast Cancer;   Metastatic Breast Cancer
Interventions:   Drug: everolimus, vinorelbine, trastuzumab;   Drug: Placebo + vinorelbine + trastuzumab
Sponsors:   Novartis;   Novartis Pharmaceuticals
Recruiting - verified May 2012

Condition:   Liver Cancer
Interventions:   Drug: cisplatin;   Drug: doxorubicin hydrochloride;   Drug: doxorubicin-eluting beads;   Drug: mitomycin C;   Drug: sorafenib tosylate;   Other: placebo
Sponsors:   National Cancer Institute (NCI);   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified April 2012

Conditions:   Solid Tumors;   Mucoepidermal Carcinoma (MEC) of the Salivary Gland;   Pigmented Villo-nodular Synovitis (PVNS);   Gastrointestinal Stromal Tumors (GIST);   Anaplastic Thyroid Carcinoma (ATC);   Solid Tumors With Documented Malignant Pleural or Peritoneal Effusions;   Malignant Peripheral Nerve Sheath Tumor (MPNST);   Neurofibromatosis Type I (NF-1);   Melanoma;   Schwannomatosis
Intervention:   Drug: PLX3397
Sponsors:   Plexxikon;   Plexxikon
Recruiting - verified May 2012

Conditions:   Advanced Solid Tumors With FGFR1 Amplication,;   Advanced Solid Tumors With FGFR2 Amplication,;   Advanced Solid Tumors With FGFR3 Mutation
Intervention:   Drug: BGJ398
Sponsors:   Novartis;   Novartis Pharmaceuticals
Recruiting - verified November 2011

Condition:   Advanced Solid Tumors
Intervention:   Drug: sapacitabine and seliciclib
Sponsors:   Cyclacel Pharmaceuticals, Inc.;   Cyclacel Pharmaceuticals, Inc.
Recruiting - verified November 2011

Condition:   Multiple Myeloma
Interventions:   Drug: Perifosine;   Drug: Perifosine Placebo;   Drug: Bortezomib;   Drug: Dexamethasone
Sponsors:   AEterna Zentaris;   AEterna Zentaris;   Dana-Farber Cancer Institute
Recruiting - verified February 2012

Condition:   Multiple Myeloma
Intervention:   Drug: BT062
Sponsors:   Biotest Pharmaceuticals Corporation;   Biotest Pharmaceuticals Corporation;   Biotest
Recruiting - verified December 2011

Condition:   Non-small Cell Lung Cancer
Intervention:   Drug: erlotinib
Sponsors:   Dana-Farber Cancer Institute;   David M. Jackman, MD;   Beth Israel Deaconess Medical Center;   Brigham and Women's Hospital;   Genentech
Recruiting - verified April 2012

Condition:   Carcinoma, Non-Small-Cell Lung
Interventions:   Drug: MM-121 (SAR256212) + erlotinib;   Drug: Erlotinib
Sponsors:   Merrimack Pharmaceuticals;   Merrimack Pharmaceuticals;   Sanofi-Aventis
Recruiting - verified January 2012

Condition:   Solid Cancers
Interventions:   Drug: GDC-0941;   Drug: GDC-0973/XL518
Sponsors:   Genentech;   Genentech
Recruiting - verified April 2012

Condition:   Acute Myeloid Leukemia
Intervention:   Drug: Plerixafor
Sponsors:   Genzyme;   Genzyme
Recruiting - verified January 2012

Conditions:   Aplastic Anemia;   Leukemia;   Myelodysplastic Syndrome
Intervention:   Other: Busulfan, fludarabine, & cyclophosphamide with immunosuppression with ATG and cyclosporine. CD34+ T-cell depleted peripheral blood stem cell transplant
Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center;   Children's Hospital Boston;   Children's Hospital Medical Center, Cincinnati;   Children's Hospital and Health System Foundation, Wisconsin;   Rockefeller University;   Fred Hutchinson Cancer Research Center
Recruiting - verified November 2011

Condition:   Bladder Cancer
Interventions:   Drug: cisplatin;   Drug: fluorouracil;   Drug: mitomycin C
Sponsors:   National Cancer Institute (NCI);   Radiation Therapy Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified April 2012

Condition:   Liver Cancer
Interventions:   Drug: cisplatin;   Drug: doxorubicin hydrochloride;   Drug: fluorouracil;   Drug: irinotecan hydrochloride;   Drug: vincristine sulfate;   Procedure: liver transplantation;   Procedure: therapeutic conventional surgery
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified November 2011

Condition:   Brain and Central Nervous System Tumors
Interventions:   Drug: cediranib maleate;   Drug: cilengitide;   Other: enzyme-linked immunosorbent assay;   Other: flow cytometry;   Other: laboratory biomarker analysis;   Procedure: magnetic resonance imaging
Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   Sidney Kimmel Comprehensive Cancer Center;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Endometrial Cancer
Interventions:   Biological: bevacizumab;   Drug: carboplatin;   Drug: ixabepilone;   Drug: paclitaxel;   Drug: temsirolimus
Sponsors:   National Cancer Institute (NCI);   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified July 2011

Condition:   Liver Cancer
Intervention:   Radiation: Proton Beam Irradiation
Sponsors:   Massachusetts General Hospital;   Massachusetts General Hospital;   Dana-Farber Cancer Institute;   Brigham and Women's Hospital;   National Cancer Institute (NCI);   M.D. Anderson Cancer Center
Recruiting - verified March 2012

Condition:   Non-small Cell Lung Cancer
Interventions:   Drug: Erlotinib;   Drug: Hydroxychloroquine
Sponsors:   Massachusetts General Hospital;   Massachusetts General Hospital;   Stanford University;   Yale University;   University of Maryland;   Genentech
Recruiting - verified April 2012

Conditions:   Lymphoma;   Nonneoplastic Condition
Interventions:   Genetic: polymerase chain reaction;   Other: laboratory biomarker analysis
Sponsors:   AIDS Malignancy Clinical Trials Consortium;   AIDS Malignancy Clinical Trials Consortium;   National Cancer Institute (NCI)
Recruiting - verified March 2012

Condition:   Pleural Effusion, Malignant
Interventions:   Other: Standard Drainage Instructions;   Other: Aggressive Drainage Instructions
Sponsors:   Duke University;   Duke University;   CareFusion
Recruiting - verified March 2012

Conditions:   Kaposiform Hemangioendotheliomas;   Tufted Angioma;   Capillary Venous Lymphatic Malformation;   Venous Lymphatic Malformation;   Microcystic Lymphatic Malformation;   Mucocutaneous Lymphangiomatosis and Thrombocytopenia;   Capillary Lymphatic Arterial Venous Malformations;   PTEN Overgrowth Syndrome With Vascular Anomaly;   Lymphangiectasia Syndromes
Intervention:   Drug: sirolimus
Sponsors:   Children's Hospital Medical Center, Cincinnati;   Children's Hospital Medical Center, Cincinnati
Recruiting - verified February 2012

Conditions:   Relapsed T-Cell Acute Lymphoblastic Leukemia;   Relapsed T-Cell Lymphoblastic Lymphoma
Interventions:   Drug: Nelarabine;   Drug: Etoposide;   Drug: Cyclophosphamide;   Drug: Methotrexate;   Drug: Filgrastim
Sponsors:   Therapeutic Advances in Childhood Leukemia Consortium;   Therapeutic Advances in Childhood Leukemia Consortium;   GlaxoSmithKline
Recruiting - verified November 2011

Condition:   Acute Lymphoblastic Leukemia
Interventions:   Drug: Prednisone;   Drug: Vincristine;   Drug: Doxorubicin;   Drug: PEG-asparaginase;   Drug: Cytarabine;   Drug: Methotrexate;   Drug: Imatinib;   Drug: Clofarabine;   Drug: 6 Mercaptopurine
Sponsors:   Massachusetts General Hospital;   Massachusetts General Hospital;   Dana-Farber Cancer Institute;   Beth Israel Deaconess Medical Center;   Enzon Pharmaceuticals, Inc.;   Genzyme
Recruiting - verified April 2012

Condition:   Cancer
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Institute of Mental Health (NIMH)
Recruiting - verified June 2011

Conditions:   Adenocarcinoma;   Her2+;   Advanced Metastatic Breast Cancer;   Metastatic ErbB2;   Invasive Breast Cancer;   Advanced Breast Cancer;   Cancer;   ErbB2+
Interventions:   Drug: Lapatinib;   Biological: Trastuzumab
Sponsors:   GlaxoSmithKline;   GlaxoSmithKline
Recruiting - verified May 2012

Conditions:   Lymphedema;   Breast Cancer
Interventions:   Device: Compression Sleeve;   Device: Short-Stretch Compression Bandage
Sponsors:   Massachusetts General Hospital;   Massachusetts General Hospital;   National Cancer Institute (NCI)
Recruiting - verified January 2012

Condition:   Metastatic Breast Cancer, Locally Recurrent Breast Cancer
Interventions:   Drug: bevacizumab;   Drug: GDC-0941;   Drug: paclitaxel
Sponsors:   Genentech;   Genentech
Recruiting - verified October 2011